Sage Journals: Discover world-class research

Abstract

The clinical success of monoclonal antibody immune checkpoint modulators such as ipilimumab, which targets cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), and the recently approved agents nivolumab and pembrolizumab, which target programmed cell death receptor 1 (PD-1), has stimulated renewed enthusiasm for anticancer immunotherapy, which was heralded by Science as ‘Breakthrough of the Year’ in 2013. As the potential of cancer immunotherapy has been recognized since the 1890s when William Coley showed that bacterial products could be beneficial in cancer patients, leveraging the immune system in the treatment of cancer is certainly not a new concept; however, earlier attempts to develop effective therapeutic vaccines and antibodies against solid tumors, for example, melanoma, frequently met with failure due in part to self-tolerance and the development of an immunosuppressive tumor microenvironment. Increased knowledge of the mechanisms through which cancer evades the immune system and the identification of tumor-associated antigens (TAAs) and negative immune checkpoint regulators have led to the development of vaccines and monoclonal antibodies targeting specific tumor antigens and immune checkpoints such as CTLA-4 and PD-1. This review first discusses the established targets of currently approved cancer immunotherapies and then focuses on investigational cancer antigens and their clinical potential. Because of the highly heterogeneous nature of tumors, effective anticancer immunotherapy-based treatment regimens will likely require a personalized combination of therapeutic vaccines, antibodies and chemotherapy that fit the specific biology of a patient’s disease.

Keywords

antitumor antibody cancer-testis antigen cancer vaccine immunotherapy oncofetal antigen tumor-associated antigen

Introduction

The possibility that immunotherapy could be useful for the treatment of cancer was first realized in the 1890s when William B. Coley showed that injecting killed bacterial cultures, known as Coley toxins, had beneficial effects in cancer patients [Nauts et al. 1953]. Decades later, studies performed in chemically induced sarcoma mouse models showed that syngeneic mice injected with irradiated sarcoma cells displayed immunity when later challenged with live sarcoma cells [Foley, 1953; Prehn and Main, 1957; Klein et al. 1960]. The fact that the immunity conferred in this manner was tumor-specific suggested that tumors express unique antigens that are specifically recognized by the adaptive immune system. Indeed, the first such tumor-associated antigen (TAA), known as melanoma antigen 1 (MAGE-1, also known as MAGE-A1), was identified in human melanoma cells by Boon and colleagues in 1991 [van der Bruggen et al. 1991]. Since that seminal discovery, the number of new TAAs has grown steadily to the point where there are now over 400 T-cell-defined human tumor antigenic peptides that have been identified [Vigneron et al. 2013]. Until the late 20th century, the role of immunosurveillance in cancer control had been the subject of much debate [Schreiber et al. 2011]; however, two studies by Schreiber and colleagues involving interferon gamma and tumor immunogenicity in immunocompetent hosts are considered to have played a major role in renewing interest in tumor immunology [Kaplan et al. 1998; Shankaran et al. 2001]. Over the years, a number of different approaches to cancer immunotherapy, including antibodies, cytokines, adoptive cell therapy (ACT) and therapeutic vaccines, have been attempted, but the overall response rates have been largely disappointing [Kirkwood et al. 2012; Savage et al. 2014]. Only recently, as knowledge of tumor biology and immunology has improved, has the complex nature of the interactions between the immune system and cancer come into focus, which has allowed the development of more specifically targeted agents [Kirkwood et al. 2012; Galluzzi et al. 2014].

Nonmutated, shared self-antigens constitute the majority of currently identified TAAs and can be classified into three major categories: (a) tumor-specific or cancer-testis antigens (CTAs), for example, MAGE-1, normally found only in the testes but are aberrantly expressed by a number of different cancers; (b) differentiation antigens expressed by both tumors and the normal differentiated cells from which the tumors arise, for example, melanoma antigen recognized by T cells (MART-1, also known as Melan-A); and (c) self-antigens that are overexpressed by tumors, for example, mucin 1 (MUC1) [Savage et al. 2014]. CTAs were the first type of TAA identified, and there are currently over 200 genes that have been classified as CTAs [Almeida et al. 2009]. It is believed that the observed antigenicity of CTAs is ascribed to the privileged immune status of the testis, where the blood–testis barrier prevents the entry of immune cells. Developing spermatozoa also do not express major histocompatibility complex (MHC) class I molecules, allowing them to evade immunosurveillance by infiltrating T cells [Whitehurst, 2014]. Thus, CTAs make attractive targets for immunotherapy; however, medullary thymic epithelial cells (mTECs) have been reported to express CTAs such as MAGE and New York esophageal squamous cell carcinoma 1 (NY-ESO-1) [Gotter et al. 2004], which suggests that central tolerance to CTAs can develop. A transcriptional regulator known as Aire (autoimmune regulator), which is expressed by mTECs, promotes the promiscuous expression of tissue-restricted antigens such as CTAs [Anderson et al. 2002; Derbinski et al. 2005], resulting in promotion of tolerance to TAAs through thymic deletion of self-reactive T cells [Savage et al. 2014].

In general, active immunotherapy of solid tumors requires the induction of cellular [T helper type 1 (T_H1) and cytotoxic T lymphocyte (CTL)-mediated] as opposed to humoral [T helper type 2 (T_H2), antibody-mediated] immune responses in order to be effective [Rosenberg, 2001; Kirkwood et al. 2012; Melero et al. 2014]. A T_H1-polarized immune response involving CTLs and natural killer (NK) cells mediates the elimination of tumor cells, while a T_H2-polarized immune response can have deleterious effects by promoting tumor development and progression [Kirkwood et al. 2012; Curigliano et al. 2013]. This is not to say that antibody-based anticancer immunotherapies are ineffective against solid tumors. Indeed, the past decade has seen the clinical development of numerous monoclonal antibodies directed at growth factors such as vascular endothelial growth factor A (VEGFA; e.g. bevacizumab), growth factor receptors such as human epidermal growth factor receptor (EGFR or HER1; e.g. cetuximab, panitumumab) and EGFR 2 (HER2; e.g. trastuzumab, pertuzumab), and negative immune checkpoint regulators such as cytotoxic T lymphocyte-associated antigen 4 (CTLA-4; e.g. ipilimumab) and programmed cell death receptor 1 (PD-1; e.g. nivolumab, pembrolizumab) [Sliwkowski and Mellman, 2013]. In addition to the direct, modulatory effects on signal transduction, antibody-dependent cellular cytotoxicity (ADCC), mediated through engagement of NK cells and macrophages, also likely contributes to the activity of these antibodies [Kohrt et al. 2012; Sliwkowski and Mellman, 2013]. The tumor-targeting monoclonal antibodies, perhaps the most commonly utilized form of anticancer immunotherapy [Weiner et al. 2010; Vacchelli et al. 2014], are examples of passive immunotherapy, while immune checkpoint inhibitors are considered to be active immunotherapies [Galluzzi et al. 2014].

The recent clinical development and approval of the immune checkpoint inhibitors ipilimumab, which targets CTLA-4, and nivolumab and pembrolizumab, both of which target PD-1, has generated a great deal of excitement in the field of cancer immunotherapy [Swaika et al. 2015]. In a phase III clinical trial, ipilimumab was the first immunotherapeutic to significantly improve overall survival (OS) in patients with advanced, metastatic melanoma [Hodi et al. 2010], and since then both nivolumab [Robert et al. 2015a] and pembrolizumab [Robert et al. 2015b] have demonstrated significant improvement in OS in this patient population. This review will first discuss CTLA-4, PD-1, and other established targets of cancer immunotherapy and then focus on novel tumor antigens and their clinical potential.

Established targets of anticancer immunotherapies

Currently approved anticancer immunotherapies, including monoclonal antibodies and cancer vaccines, target a number of different antigens including CTLA-4, PD-1, EGFR, HER2, VEGF, VEGF-R2, and PAP (prostatic acid phosphatase). Another well-known TAA is BCR-ABL (breakpoint cluster region Abelson tyrosine kinase), for which several small molecule tyrosine kinase inhibitors (TKIs) have been approved and for which immunotherapies are currently under development. Monoclonal antibodies are by far the most commonly approved form of antigen-specific anticancer immunotherapy, with only a single therapeutic cancer vaccine, sipuleucel-T (trade name Provenge^®), which targets the prostate cancer antigen PAP, having received Food and Drug Administration (FDA) approval to date. These immunotherapeutic targets and the clinical efficacy of approved treatments are discussed below. For a comprehensive list of the antigen targets of established anticancer immunotherapies, refer to Table 1.

Table 1.

Antigenic targets of approved immunotherapies.

Antigen	Cancer Types	Targeted Agents	References
BCR-ABL	CML ALL	Imatinib, Dasatinib Nilotinib, Bosutinib Ponatinib	[Isfort et al. 2014; Lindauer and Hochhaus, 2014; Ostendorf et al. 2014; Waller, 2014; Wehrle et al. 2014]
CD19	ALL	Blinatumomab	[Hoffman and Gore, 2014]
CD20	NHL, CLL B-cell NHL pre-B ALL	Rituximab Ofatumumab ⁹⁰Y-Ibritumomab ¹³¹I-Tositumomab	[Sliwkowski and Mellman, 2013; Ai and Advani, 2015]
CD30	Hodgkin’s lymphoma	Brentuximab vedotin	[Sliwkowski and Mellman, 2013; Chen and Chen, 2015]
CD33	AML	Gemtuzumab ozogamicin	[Sliwkowski and Mellman, 2013; Loke et al. 2015]
CD52	CLL	Alemtuzumab	[Skoetz et al. 2012; Sliwkowski and Mellman, 2013]
CTLA-4	Unresectable or metastatic melanoma	Ipilimumab	[Hodi et al. 2010; Robert et al. 2011; Hodi et al. 2014]
EGFR	CRC Head and Neck	Cetuximab Panitumumab	[Cunningham et al. 2004; Saltz et al. 2004; Bonner et al. 2006; Van Cutsem et al. 2007; Vermorken et al. 2008; Van Cutsem et al. 2009; Douillard et al. 2010; Price et al. 2014]
EpCAM	Malignant ascites	Catumaxomab	[Seimetz, 2011]
HER2	Breast	Trastuzumab Pertuzumab	[Slamon et al. 2001; Romond et al. 2005; Bang et al. 2010; Perez et al. 2011; O’Sullivan and Connolly, 2014; Perez et al. 2014]
PAP	Prostate	Sipuleucel-T	[Kantoff et al. 2010a]
PD-1	Metastatic melanoma NSCLC	Nivolumab Pembrolizumab	[Topalian et al. 2012; Robert et al. 2014; Topalian et al. 2014; Garon et al. 2015; Brahmer et al. 2015]
VEGF	Breast, Cervical CRC, NSCLC RCC, Ovarian Glioblastoma	Bevacizumab	[Hurwitz et al. 2004; Sandler et al. 2006; Escudier et al. 2007; Giantonio et al. 2007; Miller et al. 2007; Friedman et al. 2009; Pujade-Lauraine et al. 2014; Tewari et al. 2014]
VEGF-R2	Gastric NSCLC	Ramucirumab	[Fuchs et al. 2014; Garon et al. 2014; Wilke et al. 2014]

Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myelogenous leukemia; BCR-ABL, breakpoint cluster region Abelson tyrosine kinase; CLL, chronic lymphocytic leukemia; CTLA-4, cytotoxic T-lymphocyte-associated antigen 4; CRC, colorectal cancer; EGFR, epidermal growth factor receptor; EpCAM, epithelial cell adhesion molecule; HER2, human epidermal growth factor receptor 2; NHL, non-Hodgkin’s lymphoma; NSCLC, non-small cell lung cancer; PAP, prostatic acid phosphatase; PD-1, programmed cell death receptor 1; RCC, renal cell carcinoma; VEGF, vascular endothelial growth factor; VEGF-R2, vascular endothelial growth factor receptor 2.

Immune checkpoint blockade: CTLA-4 and PD-1

A great deal of research in cancer immunotherapy is currently being concentrated on the development of immune checkpoint modulators, particularly those targeting CTLA-4 and PD-1 and its ligands PD-L1/L2. The first checkpoint modulator to be approved, ipilimumab is a monoclonal antibody directed against CTLA-4, a molecule that downregulates the activation of T cells. A phase III clinical trial in patients with metastatic melanoma comparing ipilimumab and gp100 peptide vaccine monotherapies to the combination showed that median OS was significantly increased from 6.4 months (gp100 vaccine alone) to 10.0 months (ipilimumab plus gp100 vaccine). Ipilimumab monotherapy was equally effective [Hodi et al. 2010]. The results of this trial, which was the first demonstration of an immunotherapeutic agent significantly increasing OS in patients with metastatic melanoma, led to the approval of ipilimumab in 2011. A subsequent phase III trial in patients with metastatic melanoma showed that a combination of ipilimumab and dacarbazine significantly increased OS (11.2 versus 9.1 months) compared with dacarbazine alone [Robert et al. 2011].

Still in clinical development, tremelimumab is another anti-CTLA-4 monoclonal antibody. Unlike ipilimumab, tremelimumab failed to demonstrate any significant clinical benefit in patients with advanced melanoma [Ribas et al. 2013], although a survival benefit was revealed in patients achieving higher drug exposures following a retrospective analysis of phase II and III pharmacokinetic data [Calabro et al. 2015]. Tremelimumab is currently being developed for the treatment of malignant mesothelioma [Calabro et al. 2015], where it has demonstrated long-term clinical benefit in phase II studies [Calabro et al. 2013, 2015]. The FDA recently granted tremelimumab Orphan Drug Designation for this indication.

Two new monoclonal antibody-based therapies targeting PD-1, pembrolizumab (formerly lambrolizumab) and nivolumab, were approved by the FDA within the last year. The interaction of PD-1, expressed on the surface of activated T cells, and PD-L1 on the surface of tumor cells results in immunosuppression. An expansion cohort of a phase I trial [Hamid et al. 2013] compared pembrolizumab treatment at doses of 2 or 10 mg in metastatic melanoma patients that had progressed on ipilimumab. At both dose levels, the overall response rate, which was the primary endpoint, was 26% and the treatment was well tolerated [Robert et al. 2014]. The results of this study led to accelerated FDA approval of pembrolizumab for metastatic melanoma in September 2014, representing the first such approval of an anti-PD-1 immunotherapy. Just 3 months later, nivolumab received accelerated FDA approval for advanced melanoma on the basis of phase I/II clinical trial data showing a 31% overall response rate with a median duration of response of two years, 43% two-year survival, and a median OS of approximately 17 months [Topalian et al. 2012, 2014]. A recently published phase III trial comparing a combination of nivolumab and dacarbazine to dacarbazine alone in patients with metastatic melanoma showed significant increases in progression-free survival (PFS) and OS with the combination [Robert et al. 2015a]. Clinical trials evaluating the use of nivolumab and pembrolizumab alone and in combination with other agents such as ipilimumab, TKIs, and anti-PD-L1 agents for the treatment of a wide variety of other cancers are currently ongoing or completed, with promising results [Scott, 2015; Swaika et al. 2015].

The results of clinical trials involving pembrolizumab and nivolumab in the treatment of non-small cell lung cancer (NSCLC) and advanced melanoma were recently reported. Pembrolizumab was found to be superior to ipilimumab in the treatment of patients with advanced melanoma in a phase III clinical trial [Robert et al. 2015b]. The 6-month PFS rate was 47.3% in patients treated with pembrolizumab compared with 26.5% in patients treated with ipilimumab, and the 12-month survival rate for pembrolizumab was 74.1% compared with 58.2% for ipilimumab, differences that were highly significant. A response rate of 33.7% was seen with pembrolizumab treatment compared with 11.9% for ipilimumab, with a lower incidence of adverse events in patients treated with pembrolizumab [Robert et al. 2015b]. In a phase I study in advanced NSCLC, pembrolizumab demonstrated antitumor activity, with a response rate of 45% among patients with a PD-L1 tumor cell expression rate of at least 50%, and a response rate of 19% among all patients. Median PFS was 3.7 months among all patients and 6.3 months in patients with high PD-L1 expression [Garon et al. 2015]. The results of this trial led to the recent FDA approval of pembrolizumab for NSCLC.

Nivolumab was also recently FDA approved for the treatment of NSCLC based on the results of a phase III study showing a significant increase in OS in patients treated with nivolumab compared with docetaxel [Brahmer et al. 2015]. In previously untreated patients with unresectable stage III/IV melanoma, a randomized, double-blind phase III trial showed that nivolumab treatment, either alone or in combination with ipilimumab, was superior to ipilimumab alone, with median PFS increasing significantly from 2.9 months with ipilimumab to 6.9 and 11.5 months with nivolumab and the combination, respectively. Among patients with PD-L1-positive tumors, median PFS was 14.0 months for nivolumab alone and the combination compared to 3.9 months for ipilimumab alone [Larkin et al. 2015]. The combination of nivolumab and ipilimumab recently received accelerated FDA approval for the treatment of BRAF V600 wild-type unresectable or metastatic melanoma based on the results of a phase II trial [Postow et al. 2015]. This was the first approval of an immunotherapy combination for cancer patients.

Investigational, PD-1-targeted agents still in clinical development include pidilizumab, which has been evaluated in phase II clinical trials in patients with B-cell lymphoma [Armand et al. 2013] and metastatic melanoma [Atkins et al. 2014], AMP-514 (MEDI0680), being evaluated in ongoing phase I trials in patients with advanced malignancies [ClinicalTrials.gov identifiers: NCT02118337; NCT02013804], and AMP-224, which is currently being evaluated in a phase I trial [ClinicalTrials.gov identifier: NCT02298946] in patients with metastatic colorectal cancer (CRC) [Homet Moreno et al. 2015].

EGFR receptor tyrosine kinase family

The human epidermal growth factor receptor (EGFR or HER1) is a receptor tyrosine kinase (RTK) that is overexpressed in a variety of different cancers including lung, breast and colon cancer. Specific mutations in the EGFR proto-oncogene result in the RTK becoming constitutively active [Chung, 2015]. Upon activation, EGFR stimulates a number of different signaling pathways, for example, MAPK (mitogen-activated protein kinase), PI3K (phosphoinositide 3-kinase) and STAT (signal transducer and activator of transcription), which lead to cancer cell proliferation and survival [Hynes and Lane, 2005]. This has made EGFR an attractive target for immunotherapy, and indeed several different monoclonal antibodies as well as small molecule TKIs have been developed and approved [Sliwkowski and Mellman, 2013]. Among these, gefitinib, erlotinib and afatinib are TKIs approved for the treatment of NSCLC. While TKIs are quite effective in treating EGFR mutation-positive NSCLC, the development of resistance is virtually universal, commonly through the T790M mutation [Pao et al. 2005]. Interestingly, a peptide antigen derived from the T790M EGFR mutation has been reported to be immunogenic and is a potential target for antigen-specific immunotherapy [Yamada et al. 2013; Ofuji et al. 2015].

Cetuximab and panitumumab

Approved monoclonal antibodies targeting EGFR include cetuximab for colon and head and neck cancers, and panitumumab for colon cancer. Cetuximab received accelerated FDA approval in 2004 for the treatment of metastatic CRC refractory to irinotecan based on the results of clinical trials showing acceptable safety [Saltz et al. 2004] and significant increases in overall response rate and time to progression in patients treated with a combination of cetuximab and irinotecan [Cunningham et al. 2004]. Phase III clinical trial data reaffirming prior results and demonstrating significant increases in PFS and OS in patients with refractory metastatic CRC [Jonker et al. 2007; Sobrero et al. 2008] led to regular FDA approval of single-agent cetuximab in 2007 for the treatment of chemotherapy-refractory metastatic CRC. More recently, cetuximab received FDA approval in 2012 as first-line treatment for metastatic CRC based on the results of the phase III CRYSTAL trial [Van Cutsem et al. 2009] and supporting trials [Bokemeyer et al. 2009, 2012]. A pooled analysis of these trials showed that cetuximab combined with chemotherapy significantly increased overall response rate, PFS and OS in patients with KRAS wild type, EGFR-expressing metastatic CRC [Bokemeyer et al. 2012].

Cetuximab is also used in the treatment of squamous cell carcinoma of the head and neck (SCCHN), having received FDA approval in 2006 for single-agent use in recurrent/metastatic SCCHN refractory to platinum-based chemotherapy, and in combination with radiotherapy for locally or regionally advanced SCCHN. This approval was based on the results of a phase III clinical trial showing significant increases in PFS, median duration of locoregional control and OS with cetuximab plus radiotherapy compared to radiotherapy alone in patients with locoregionally advanced SCCHN [Bonner et al. 2006], and a phase II study in patients with refractory recurrent/metastatic SCCHN showing a 13% response rate and median OS of approximately 6 months with cetuximab monotherapy [Vermorken et al. 2007]. Cetuximab was subsequently approved as first-line therapy in combination with chemotherapy for recurrent/metastatic SCCHN on the strength of the results of a phase III clinical trial showing significant increases in median OS, PFS and response rate with the combination of cetuximab and chemotherapy compared with chemotherapy alone in patients with recurrent/metastatic SCCHN [Vermorken et al. 2008]. The activity of cetuximab has also been evaluated in NSCLC, where a meta-analysis of four phase II/III clinical trials showed that the combination of cetuximab and first-line chemotherapy slightly, yet significantly, increased OS compared with platinum-based chemotherapy alone [Pujol et al. 2014].

Panitumumab is also used in the treatment of metastatic CRC. The results of a phase III clinical trial showing significant increases in PFS and response rate in patients with chemotherapy-refractory metastatic CRC led to the accelerated FDA approval of panitumumab in 2006 [Van Cutsem et al. 2007]. Panitumumab was most recently approved in 2014 as first-line treatment in combination with chemotherapy in KRAS wild-type, metastatic CRC following the results of phase III clinical trials showing a significant increase in PFS, an increase in OS [Douillard et al. 2010], and noninferiority with cetuximab [Price et al. 2014].

Trastuzumab

Trastuzumab is a monoclonal antibody used for the treatment of breast cancer overexpressing the human EGFR 2 (HER2) oncogene, which includes approximately 15–30% of breast cancers and is associated with a poor prognosis [Slamon et al. 1987, 1989]. The FDA first approved trastuzumab in combination with chemotherapy in 1998 for the first-line treatment of patients with metastatic breast cancer. This original approval was based on the results of a phase III clinical trial showing that treatment with trastuzumab plus standard chemotherapy significantly increased time to progression, response rate, duration of response and OS compared with chemotherapy alone [Slamon et al. 2001]. Based on clinical trials data showing significant increases in disease-free survival (DFS) and OS [Romond et al. 2005; Perez et al. 2011, 2014], trastuzumab later received FDA approval in 2006 for the treatment of breast cancer in the adjuvant setting in combination with chemotherapy. Trastuzumab was most recently approved in 2010 for the first-line treatment of metastatic gastric or gastro-esophageal junction adenocarcinoma in combination with chemotherapy based on a phase III clinical trial showing significantly increased OS following treatment with trastuzumab combined with chemotherapy [Bang et al. 2010]. Currently, trastuzumab in combination with pembrolizumab is being evaluated in a phase I/II clinical trial in patients with trastuzumab-resistant, HER2-positive metastatic breast cancer [ClinicalTrials.gov identifier: NCT02129556]. It has been previously shown that trastuzumab and anti-PD-1 treatment are synergistic in mice [Stagg et al. 2011].

Necitumumab

Still in clinical development, necitumumab is a second-generation anti-EGFR monoclonal antibody currently being evaluated for the treatment of NSCLC. Recently published data from a phase III clinical trial in 1093 patients with stage IV squamous NSCLC showed that necitumumab in combination with chemotherapy as first-line treatment resulted in a modest survival benefit, with a median OS of 11.5 months in patients treated with necitumumab plus chemotherapy compared with 9.9 months in patients treated with chemotherapy alone, a difference that was significant [Thatcher et al. 2015]. In patients with stage IV nonsquamous NSCLC, however, combining necitumumab with standard chemotherapy as first-line treatment provided no additional clinical benefit compared with chemotherapy alone [Paz-Ares et al. 2015].

VEGFA and VEGF-R2

Vascular endothelial growth factor A (VEGFA) plays a critical role in angiogenesis, and it is the target of the monoclonal antibody bevacizumab. In addition to its anti-angiogenic effects [Ferrara et al. 2004], bevacizumab has been found to augment tumor infiltration by T and B lymphocytes [Manzoni et al. 2010; Hodi et al. 2014] and to inhibit regulatory T cells (Tregs) [Terme et al. 2013]. Bevacizumab has been FDA approved for the treatment of CRC (2004), glioblastoma (2009), cervical cancer (2014), lung cancer (2006), renal cell cancer (2009), breast cancer (2008), and ovarian cancer (2014).

Bevacizumab was initially approved for the first-line treatment of metastatic CRC in combination with chemotherapy based on a phase III study showing significant increases in PFS and median OS compared with chemotherapy alone [Hurwitz et al. 2004]. Shortly thereafter, bevacizumab received approval as second-line treatment in combination with chemotherapy for patients with previously treated metastatic CRC following the results of a phase III clinical trial showing significant improvement in PFS and median OS [Giantonio et al. 2007] compared with chemotherapy alone. Two years later, another Phase III trial in patients with recurrent or advanced NSCLC showed significant increases in response rate, PFS and OS following treatment with bevacizumab plus chemotherapy [Sandler et al. 2006], which led to approval of bevacizumab combined with chemotherapy as first-line treatment of recurrent/advanced NSCLC. The approval of bevacizumab as first-line treatment of metastatic breast cancer was supported by the results of a phase III clinical trial in patients with HER2-negative metastatic breast cancer showing that treatment with bevacizumab and paclitaxel led to significant increases in PFS and objective response rate (ORR) compared with paclitaxel alone [Miller et al. 2007]. A phase II study used to support the 2009 FDA approval of bevacizumab combined with chemotherapy for patients with recurrent glioblastoma showed that treatment with bevacizumab combined with chemotherapy resulted in improved PFS and ORR, differences that were significant compared to expected effects of salvage chemotherapy [Friedman et al. 2009]. The same year, bevacizumab combined with interferon α was approved as first-line treatment of metastatic renal cell carcinoma (RCC) based on phase III data demonstrating significant improvement in PFS [Escudier et al. 2007]. No significant improvement in OS was observed in this trial [Escudier et al. 2010]. Most recently, bevacizumab was approved in 2014 for the treatment of recurrent or metastatic cervical cancer and recurrent, platinum-refractory ovarian carcinoma based on phase III clinical trials showing significant increases in OS and response rate in cervical cancer [Tewari et al. 2014], and significant improvement in PFS and ORR in ovarian cancer [Pujade-Lauraine et al. 2014], compared with chemotherapy alone. Like trastuzumab, bevacizumab and anti-PD-1 combination treatment is currently being clinically evaluated [ClinicalTrials.gov identifiers: NCT02210117; NCT02039674; NCT02348008].

VEGF-R2, also known as KDR (kinase insert domain receptor) and Flk-1 (fetal liver kinase 1), is an RTK and the primary receptor through which VEGF mediates its angiogenic, mitogenic, and permeability-enhancing effects [Ferrara et al. 2004]. A monoclonal antibody that targets VEGF-R2, ramucirumab has received FDA approval for the second-line treatment of gastric cancer and NSCLC within the past year. Ramucirumab was approved as monotherapy and in combination with paclitaxel for the treatment of gastric or gastroesophageal junction adenocarcinoma after progression on first-line chemotherapy based on the results of two phase III trials showing significant increases in median OS compared with placebo [Fuchs et al. 2014] and paclitaxel plus placebo [Wilke et al. 2014]. Efficacy as second-line treatment for metastatic NSCLC after progression on platinum-based chemotherapy was also demonstrated in a phase III trial showing significant improvement in PFS and OS with the combination of docetaxel and ramucirumab compared with docetaxel plus placebo [Garon et al. 2014].

PAP

PAP is the target of the only currently FDA-approved therapeutic anticancer vaccine, sipuleucel-T (Provenge^®). Sipuleucel-T was approved for the treatment of asymptomatic and minimally symptomatic metastatic castration-resistant prostate cancer in 2010 based on the results of the phase III IMPACT trial showing a significant increase in median OS in patients treated with sipuleucel-T compared with those treated with placebo [Kantoff et al. 2010a]. To prepare sipuleucel-T, peripheral blood mononuclear cells from the patient are cultured with a fusion protein that incorporates PAP and GM-CSF (granulocyte-macrophage colony-stimulating factor). The patient is then infused with these cells, and the process is repeated for three cycles. Thus, sipuleucel-T is actually a combination of a cell-based vaccine and autologous ACT [Melero et al. 2014]. Interestingly, in addition to immune responses against the primary antigenic target PAP, humoral immune responses against several secondary antigens such as PSA (prostate specific antigen), K-ras and KLK2/hK2 were also observed to be elevated in patients treated with sipuleucel-T but not control in the phase III IMPACT trial, and these responses were associated with improved OS [GuhaThakurta et al. 2015].

Investigational tumor antigens and their clinical potential

In addition to the established tumor antigens for which targeted immunotherapies have already been approved (Table 1), there are numerous novel tumor antigens currently being investigated as potential targets for new immunotherapies, including MUC1, PD-L1, lymphocyte activation gene 3 (LAG-3), T-cell immunoglobulin domain and mucin domain 3 (TIM-3), V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA), NY-ESO-1, carcinoembryonic antigen (CEA), PSA, MAGE-A3, 5T4, survivin and indoleamine-2,3-dioxygenase (IDO1). These selected antigens and their clinical potential as targets for investigational immunotherapies are discussed below. Table 2 includes a more complete listing of tumor antigen targets for which immunotherapies are currently being explored.

Table 2.

Antigenic targets of investigational immunotherapies.

Antigen	Cancer types	Targeted agents	References
A2aR	NSCLC	PBF-509	[Pinna, 2014]
AKAP4	NSCLC Ovarian	Preclinical	[Agarwal et al. 2013; Mirandola et al. 2015]
BAGE	Glioblastoma Ovarian	Preclinical	[Zhang et al. 2010; Akiyama et al. 2014]
BORIS	Prostate, Lung Esophageal	Preclinical	[Okabayashi et al. 2012; Cheema et al. 2014; Lee et al. 2014]
CD22	ALL	Epratuzumab Moxetumomab Inotuzumab ozogamicin	[Raetz et al. 2008; Advani et al. 2014; Annesley and Brown, 2015; Raetz et al. 2015]
CD73	Advanced solid tumors	MEDI9447	[Hay et al. 2015]
CD137	Advanced solid tumors	Urelumab PF-05082566	[Yonezawa et al. 2015]
CEA	CRC	PANVAC™ Ad5-[E1-, E2b-]-CEA(6D)	[Turriziani et al. 2012; Morse et al. 2013a, 2013b]
CS1	Multiple myeloma	Elotuzumab	[Veillette and Guo, 2013]
CTLA-4	Malignant mesothelioma	Tremelimumab	[Calabro et al. 2015]
EBAG9	Bladder	Preclinical	[Miyazaki et al. 2014]
EGF	NSCLC	CIMAvax	[Gonzalez et al. 2007; Neninger Vinageras et al. 2008; Cheng and Kananathan, 2012; Ruiz et al. 2014]
EGFR	NSCLC	Necitumumab	[Thatcher et al. 2015]
GAGE	Cervical	Preclinical	[Kular et al. 2010]
GD2	Neuroblastoma Retinoblastoma Melanoma other solid tumors	Dinutuximab, hu3F8 hu14.18-IL-2, 3F8/OKT3BsAb anti-GD2 CAR GD2-KLH	[Suzuki and Cheung, 2015]
gp100	Melanoma	gp100:209-217(210M)	[Schwartzentruber et al. 2011]
HPV-16	Cervical SCCHN	HPV-16 (E6, E7) TG4001, Lm-LLO-E7 pNGVL4a-CRT/E7, INO-3112	[Kenter et al. 2009; Brun et al. 2011; Bagarazzi et al. 2012; Zaravinos, 2014]
HSP105	CRC Bladder	Preclinical	[Zappasodi et al. 2011; Kawai et al. 2014; Sawada et al. 2014]
IDH1	Glioma	IDH1(R132H) p123-142	[Schumacher et al. 2014]
Idiotype (NeuGcGM3)	NSCLC, Breast Melanoma	Racotumomab	[Alfonso et al. 2002, 2014; Diaz et al. 2003]
IDO1	Breast, Melanoma NSCLC	Indoximod INCB024360 IDO1 peptide vaccine	[Iversen et al. 2014, 2015; Soliman et al. 2014]
KIR	Lymphoma	Lirilumab	[Kohrt et al. 2014]
LAG-3	Breast, Hemato- logical, Advanced solid tumors	BMS-986016 IMP321	[Brignone et al. 2010; Creelan, 2014; Nguyen and Ohashi, 2015]
LY6K	Gastric SCCHN	LY6K-177 peptide LY6K, CDCA1, IMP3	[Ishikawa et al. 2014; Yoshitake et al. 2015]
MAGE-A3	Melanoma NSCLC	recMAGE-A3 Zastumotide	[Kruit et al. 2013; Ulloa-Montoya et al. 2013; Vansteenkiste et al. 2013; Melero et al. 2014]
MAGE-C2	Gastric, Melanoma Multiple myeloma	Preclinical	[Zhang et al. 2013; Ghadban et al. 2014; Reinhard et al. 2014]
MAGE-D4	CRC	Preclinical	[Zhang et al. 2014]
Melan-A	Melanoma	MART-1 (26-35, 27L)	[Tarhini et al. 2012; Romano et al. 2014]
MET	NSCLC	Onartuzumab Tivantinib	[Scagliotti et al. 2012; Spigel et al. 2013; Stinchcombe, 2014]
MUC1	NSCLC, Breast Prostate	Tecemotide, TG4010 PANVAC™	[Kimura and Finn, 2013; Butts et al. 2014; Wurz et al. 2014]
MUC4	Pancreatic	Preclinical	[Wu et al. 2009; Torres et al. 2012; Zhu et al. 2014]
MUC16	Ovarian	Abagovomab Oregovomab	[Buzzonetti et al. 2014; Felder et al. 2014]
NY-ESO-1	Ovarian Melanoma	NY-ESO-1/ISCOMATRIX™ rV-NY-ESO-1; rF-NY-ESO-1	[Robbins et al. 2011; Odunsi et al. 2012; Klein et al. 2015]
PD-1	B-cell lymphoma Melanoma, CRC	Pidilizumab AMP-224, AMP-514	[Armand et al. 2013; Homet Moreno et al. 2015]
PD-L1	NSCLC, RCC Bladder, Breast Melanoma, SCCHN	BMS-936559, Atezolizumab Durvalumab, Avelumab	[Cha et al. 2015; Ibrahim et al. 2015; Sunshine and Taube, 2015; Swaika et al. 2015]
PRAME	NSCLC	Preclinical	[De Pas et al. 2012]
PSA	Prostate	PROSTVAC^®-VF	[Gulley et al. 2010; Kantoff et al. 2010b; Shore, 2014]
ROR1	CLL, Pancreatic Lung, Breast	Preclinical	[Hojjat-Farsangi et al. 2014; Berger et al. 2015; Shabani et al. 2015]
Sialyl-Tn	Breast	Theratope	[Miles et al. 2011; Ibrahim et al. 2013]
SPAG-9	Prostate, CRC NSCLC, Ovarian	Preclinical	[Garg et al. 2007; Kanojia et al. 2011; Wang et al. 2013; Chen et al. 2014]
SSX1	Prostate Multiple myeloma	Preclinical	[Smith et al. 2011; He et al. 2014]
Survivin	Melanoma Glioma, Solid tumors	EMD640744 Trivalent peptide vaccine Tripeptide vaccine	[Becker et al. 2012; Lennerz et al. 2014; Pollack et al. 2014]
Telomerase	Pancreatic	Tertomotide	[Melero et al. 2014; Staff et al. 2014]
TIM-3	Melanoma, NHL NSCLC	Preclinical	[Sakuishi et al. 2010; Ngiow et al. 2011; Gao et al. 2012; Fourcade et al. 2014; Jiang et al. 2015]
VISTA	Melanoma, Bladder	Preclinical	[Le Mercier et al. 2014; Lines et al. 2014b]
WT1	Ovarian, Uterine, AML Multiple myeloma	WT1 peptide vaccine	[Coosemans et al. 2014; Di Stasi et al. 2015]
XAGE-1b	Prostate	DC-based tumor vaccine	[Zhou et al. 2008; Xie and Wang, 2015]
5T4	RCC, CRC Prostate	TroVax^® Naptumomab estafenatox	[Amato et al. 2010; Zhang et al. 2012; Harrop et al. 2013; Eisen et al. 2014; Rowe and Cen, 2014; Stern et al. 2014]

Abbreviations: A2aR, adenosine A2a receptor; AKAP4, A kinase anchor protein 4; AML, acute myelogenous leukemia; ALL, acute lymphoblastic leukemia; BAGE, B melanoma antigen; BORIS, brother of the regulator of imprinted sites; CEA, carcinoembryonic antigen; CLL, chronic lymphocytic leukemia; CRC, colorectal cancer; CS1, CD2 subset 1; CTLA-4, cytotoxic T-lymphocyte-associated antigen 4; EBAG9, estrogen receptor binding site associated antigen 9; EGF, epidermal growth factor; EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer; GAGE, G antigen; GD2, disialoganglioside GD2; gp100, glycoprotein 100; HPV-16, human papillomavirus 16; HSP105, heat-shock protein 105; IDH1, isocitrate dehydrogenase type 1; IDO1, indoleamine-2,3-dioxygenase 1; KIR, killer cell immunoglobulin-like receptor; LAG-3, lymphocyte activation gene 3; LY6K, lymphocyte antigen 6 complex K; MAGE-A3, melanoma antigen 3; MAGE-C2, melanoma antigen C2; MAGE-D4, melanoma antigen D4; Melan-A/MART-1, melanoma antigen recognized by T-cells 1; MET, N-methyl-N’-nitroso-guanidine human osteosarcoma transforming gene; MUC1, mucin 1; MUC4, mucin 4; MUC16, mucin 16; NHL, non-Hodgkin lymphoma; NY-ESO-1, New York esophageal squamous cell carcinoma 1; PD-1, programmed cell death receptor 1; PD-L1, programmed cell death receptor ligand 1; PRAME, preferentially expressed antigen of melanoma; PSA, prostate specific antigen; RCC, renal cell carcinoma; ROR1, receptor tyrosine kinase orphan receptor 1; SCCHN, squamous cell carcinoma of the head and neck; SPAG-9, sperm-associated antigen 9; SSX1, synovial sarcoma X-chromosome breakpoint 1; TIM-3, T-cell immunoglobulin domain and mucin domain-3; VISTA, V-domain immunoglobulin-containing suppressor of T-cell activation; WT1, Wilms’ Tumor-1; XAGE-1b, X chromosome antigen 1b.

MUC1

Mucin 1 (MUC1) is one of the best-characterized TAAs, and it is overexpressed and aberrantly glycosylated in over 90% of adenocarcinomas such as lung and breast cancer [Szabo, 2003; Brayman et al. 2004]. MUC1 is a transmembrane glycoprotein expressed in several epithelial tissues, but the normal glycosylation pattern shields the peptide core of the extracellular domain from immunosurveillance. In cancer, the aberrant underglycosylation of MUC1 leads to exposure of the immunogenic tandem repeat regions of the core peptide, making MUC1 an attractive target for immunotherapies [Apostolopoulos and McKenzie, 1994; Vlad et al. 2004].

While several different MUC1-targeted immunotherapies have been assessed in clinical trials [Kimura and Finn, 2013], the most advanced agent is tecemotide, an antigen-specific, liposome-based, peptide cancer vaccine [Wurz et al. 2014] that has been evaluated in a phase III clinical trial as maintenance therapy for patients with locally advanced, unresectable stage IIIA/IIIB NSCLC who had not progressed following primary chemoradiotherapy [Butts et al. 2014]. The results failed to demonstrate significant improvement in OS with tecemotide compared with placebo; however, a predefined subgroup analysis of the patients who received concurrent chemoradiotherapy followed by tecemotide showed a significant survival benefit, while no survival benefit was seen with sequential chemoradiotherapy [Butts et al. 2014]. After approximately 20 months of additional follow up, the survival benefit of tecemotide following concurrent chemoradiotherapy remained significant [Mitchell et al. 2015]. These results suggest that the timing of radiotherapy, chemotherapy and immunotherapy is important and that monitoring immune status may be necessary when designing treatment regimens combining immunotherapy with chemoradiotherapy [Kao et al. 2014, 2015]. Another phase III trial, recently discontinued, was initiated to study tecemotide maintenance therapy following concurrent chemoradiotherapy in NSCLC [DeGregorio et al. 2014].

Immune checkpoints: PD-L1; LAG-3; TIM-3; VISTA

PD-L1

As already mentioned, the development of immune checkpoint inhibitors is currently the focus of intense research efforts. The interaction of PD-L1, which is expressed on the surface of tumor cells, with PD-1 on activated T cells results in immunosuppression and tumor immune escape [Iwai et al. 2002; Swaika et al. 2015]. PD-L1 expression has been found to be inducible by interferon γ [Muhlbauer et al. 2006]. Several investigational immunotherapies targeting PD-L1 are presently in clinical development for metastatic melanoma, NSCLC, RCC and bladder cancer, among others.

BMS-936559 (MDX-1105) is a monoclonal antibody that inhibits the binding of PD-L1 to both PD-1 and CD80. The safety and antitumor activity of BMS-936559 in patients with a variety of advanced cancers have been evaluated in a phase I clinical trial involving 207 patients [Brahmer et al. 2012]. In NSCLC, an ORR of 10% (all partial responses) and PFS rate of 31% at 24 weeks were observed. Patients with RCC showed a 12% ORR and 53% progression-free response rate at 24 weeks. In ovarian cancer, an ORR of only 6% was observed [Brahmer et al. 2012]. No more recent clinical data regarding BMS-936559 in cancer therapy have emerged, and it appears that clinical development of this agent for oncology applications has been discontinued [Mullard, 2013; Sunshine and Taube, 2015].

Atezolizumab (MPDL3280A) is an anti-PD-L1 monoclonal antibody that has demonstrated activity against a variety of advanced cancers in phase I clinical trials. The Fc region of the antibody is modified to prevent both ADCC and complement-dependent cytotoxicity (CDC) [Lu et al. 2014], which prevents the killing of immune cells that also express PD-L1, such as activated T cells. Atezolizumab is currently being evaluated in patients with locally advanced or metastatic solid tumors in an ongoing phase I study. In a cohort of patients with metastatic urothelial bladder cancer, an ORR of 43% was observed at 6 weeks, increasing to 52% at 12 weeks of treatment [Powles et al. 2014]. As there had been no significant advances in the treatment of metastatic urothelial cancer in decades, these results led to breakthrough designation status by the FDA in June 2014. Updated response and survival data from this study after an additional 8 months of follow up continued to show promising PFS and OS results [Petrylak et al. 2015]. For patients with NSCLC, an ORR of 23% and PFS rate of 45% at 24 weeks was seen with atezolizumab treatment [Herbst et al. 2014], and the most recent data continued to show clinical benefit in NSCLC [Horn et al. 2015]. Atezolizumab has also been studied in combination with first-line chemotherapy in metastatic NSCLC patients, and was found to improve ORR in all combinations tested in a phase Ib trial [Liu et al. 2015b]. In patients with metastatic melanoma or RCC, ORRs of 30% and 14%, and PFS rates of 41% and 48% at 24 weeks, respectively, were observed [Herbst et al. 2014]. Patients in the triple-negative breast cancer cohort had an ORR of 19% and a PFS rate of 27% at 24 weeks [Emens et al. 2015].

Preliminary results from two phase II clinical trials of atezolizumab in patients with advanced NSCLC were recently reported. In both chemotherapy-naïve and previously treated patients, an increasing ORR to atezolizumab treatment was associated with increasing PD-L1 expression [Spigel et al. 2015]. Compared with docetaxel in previously treated NSCLC, treatment with atezolizumab was found to increase OS, PFS and ORR in association with PD-L1 expression [Spira et al. 2015]. There are currently several other phase I/II and phase III clinical trials of atezolizumab currently underway [Swaika et al. 2015].

Durvalumab (MEDI4736) is an anti-PD-L1 monoclonal antibody similar to atezolizumab, with an Fc region modification that prevents ADCC and CDC. In a phase I clinical trial, response rates of 13% and 14% were observed in patients with metastatic NSCLC and SCCHN, respectively [Lee and Chow, 2014]. A phase II study [ClinicalTrials.gov identifier: NCT02336165] in patients with glioblastoma multiforme is currently underway [Reardon et al. 2015]. Durvalumab has also entered a phase III clinical trial in combination with concurrent chemoradiotherapy in patients with stage III unresectable NSCLC [ClinicalTrials.gov identifier: NCT02125461] and a phase II/III clinical trial [ClinicalTrials.gov identifier: NCT02154490] in patients with recurrent stage IIIB/IV squamous cell NSCLC [Lee and Chow, 2014; Ibrahim et al. 2015]. Other ongoing phase II and phase III clinical trials of durvalumab include third-line treatment of stage IIIB/IV NSCLC [ClinicalTrials.gov identifier: NCT02087423], second-line treatment of SCCHN [ClinicalTrials.gov identifier: NCT02207530; Ibrahim et al. 2015] and treatment of advanced NSCLC alone or in combination with tremelimumab [ClinicalTrials.gov identifier: NCT02352948; Planchard et al. 2015].

A fourth anti-PD-L1 monoclonal antibody, avelumab (MSB0010718C), is currently in phase I development in subjects with metastatic or locally advanced solid tumors [ClinicalTrials.gov identifier: NCT01772004], with a separate phase I trial in Japanese subjects [Lu et al. 2014]. Results of this phase I trial in extensively pretreated patients with a variety of different tumors have so far demonstrated that avelumab has an acceptable safety profile [Kelly et al. 2015]. A phase Ib expansion study in advanced NSCLC patients who had progressed after platinum-based chemotherapy demonstrated increased activity with avelumab treatment in patients with PD-L1-positive tumors [Gulley et al. 2015]. A phase II study of avelumab in patients with metastatic Merkel cell carcinoma is currently underway [Kaufman et al. 2015]. Interestingly, unlike the other anti-PD-L1 antibodies being developed, avelumab appears to possess ADCC activity [Boyerinas et al. 2015].

LAG-3

LAG-3 is a negative regulator of effector T-cell function [Sierro et al. 2011], making it an attractive target for immunotherapy. LAG-3 is expressed on the membranes of activated T cells and is upregulated on exhausted T cells [Nguyen and Ohashi, 2015]. Because LAG-3 is also expressed on activated Tregs, LAG-3 blockade may inhibit the suppressive effects of Tregs in addition to the direct action on effector cells [Huang et al. 2004]. The major ligand of LAG-3 is MHC class II, and their interaction may play a role in modulating dendritic cell function [Goldberg and Drake, 2011; Camisaschi et al. 2014]. A monoclonal antibody targeting LAG-3, known as BMS-986016, is currently in early phase I clinical development. Ongoing clinical trials are investigating single agent BMS-986016 for hematological malignancies and a combination of nivolumab and BMS-986016 in patients with advanced solid tumors [Creelan, 2014; Nguyen and Ohashi, 2015]. In addition to the membrane-bound form of LAG-3, the LAG3 gene also codes for a soluble variant, sLAG-3, that functions as an immune adjuvant [Nguyen and Ohashi, 2015]. A sLAG-3 immunoglobulin fusion protein (IMP321) is in early clinical development as an immune adjuvant. In a Phase I clinical trial evaluating a combination of taxane-based chemotherapy and IMP321 in women with metastatic breast cancer, a 50% ORR was observed [Brignone et al. 2010].

TIM-3

TIM-3 is an inhibitory immune checkpoint receptor that limits the duration and magnitude of T_H1 CD4+ and CD8+ CTL cellular responses [Anderson, 2014]. Galectin-9 has been identified as the ligand for TIM-3, and it is through this pathway that T_H1 immunity may be suppressed [Zhu et al. 2005]. The expression of TIM-3 on dysfunctional CD8+ T cells and Tregs makes it an attractive target for anticancer immunotherapy. Preclinical animal models have shown that antibody inhibition of TIM-3 is very effective in suppressing tumor growth [Ngiow et al. 2011]. Synergistic antitumor effects in multiple cancer types have been observed in preclinical models with the combination of anti-PD-1/PD-L1 and TIM-3 blockade [Sakuishi et al. 2010; Ngiow et al. 2011; Jing et al. 2015]. Clinically, increased expression of TIM-3 and PD-1 in melanoma patients has been associated with tumor NY-ESO-1-specific CD8+ T-cell dysfunction [Fourcade et al. 2014]. In NSCLC, TIM-3 is expressed on tumor-infiltrating CD4+ and CD8+ T cells [Gao et al. 2012], and the presence of CD4+ T cells that express TIM-3 is strongly correlated with advanced tumor grade in NSCLC [Gao et al. 2012] and poor survival in follicular B-cell non-Hodgkin lymphoma [Yang et al. 2012]. Thus, TIM-3 has great clinical potential as a target of novel immunotherapies [Cheng and Ruan, 2015].

VISTA

VISTA is a newly identified negative immune checkpoint regulator [Lines et al. 2014b]. Unlike PD-L1, VISTA is expressed primarily in hematopoietic cells in both mice [Wang et al. 2011] and humans [Lines et al. 2014a]. In murine models of melanoma and bladder cancer, leukocytes within the tumor microenvironment and in tumor-draining lymph nodes were found to have elevated VISTA expression. Treatment with an anti-VISTA monoclonal antibody resulted in tumor growth inhibition, especially in combination with a tumor vaccine [Le Mercier et al. 2014]. In these studies, VISTA blockade was found to be effective with no detectable expression of VISTA and high expression levels of PD-L1 on tumor cells. This observation could have important clinical implications for combination treatments targeting the VISTA and PD-1/PD-L1 checkpoint pathways, allowing for potential synergy due to the fact that these pathways operate independently [Lines et al. 2014b; Liu et al. 2015a].

CTAs: NY-ESO-1 and MAGE-A3

CTAs constitute the majority of the currently identified TAAs, and numerous CTAs are being investigated as potential targets of new anticancer immunotherapies for a variety of malignancies. Among these, immunotherapies targeting NY-ESO-1 and MAGE-A3 have reached the clinical stage of development. These antigens are normally expressed only in adult testis germ cells and become aberrantly re-expressed in various cancers such as lung, bladder and melanoma [Jungbluth et al. 2001].

NY-ESO-1

NY-ESO-1 is encoded by the CTAG1B gene and was first identified in 1997 [Chen et al. 1997]. Expressed in a variety of carcinomas and sarcomas, NY-ESO-1 is highly immunogenic and is thus a logical target for anticancer immunotherapy [Nicholaou et al. 2006; Endo et al. 2015]. In a phase I clinical trial in patients with advanced synovial cell sarcoma and melanoma, subjects were administered autologous ACT using cells transduced with a T-cell receptor (TCR) targeting NY-ESO-1. Objective response rates of 67% (4/6) and 45% (5/11) were observed for synovial cell sarcoma and melanoma patients, respectively [Robbins et al. 2011]. Autologous ACT has also been performed using NY-ESO-1-specific CD4+ cells [Hunder et al. 2008]. A prime-boost vaccine strategy was assessed in patients with stage III/IV melanoma and stage II-IV ovarian carcinoma in a phase II clinical trial. Patients were primed with a recombinant NY-ESO-1-expressing vaccinia virus and then boosted with an NY-ESO-1-expressing fowlpox virus. In the melanoma patients, CD8+ T-cell responses increased from 40% pretreatment to 88% following vaccination. Median OS was significantly increased in the melanoma and ovarian cancer patients who had immune responses following treatment [Odunsi et al. 2012]. An NY-ESO-1-specific vaccine (NY-ESO-1/ISCOMATRIX™) in combination with cyclophosphamide has also been evaluated in advanced melanoma in phase II. Treatment led to a significant increase in antigen-specific CD4+ T-cell immune responses [Klein et al. 2015] compared to a cohort of patients treated with the vaccine alone [Nicholaou et al. 2009]. A prime-boost treatment strategy employing NY-ESO-1/ISCOMATRIX™ in high-risk, resected melanoma patients was found to augment CD8+ T-cell immune responses [Chen et al. 2015].

MAGE-A3

MAGE-A3 is a CTA that has been extensively clinically investigated as a target for immunotherapy in melanoma and lung cancer. In a clinical trial involving nine patients with advanced cancers, five responses were observed following autologous ACT with T cells transduced with anti-MAGE-A3 TCRs. However, neurological toxicities were seen in three patients, resulting in two deaths due to previously unknown expression of MAGE family antigens in the brain [Morgan et al. 2013]. A Phase II study examined vaccination with recombinant MAGE-A3 protein combined with either AS15 [a combination of QS21 saponin, monophosphoryl lipid A (MPL-A), and CpG7909, a Toll-like receptor (TLR)-9 agonist, in a liposomal formulation] or AS02_B (a combination of QS21 saponin and MPL-A, a TLR-4 agonist) immunostimulants in patients with stage III/IV melanoma. Trends towards greater ORR, PFS and median OS were observed in the patients who received the AS15 immunostimulant compared with AS02_B [Kruit et al. 2013]. The peptide vaccine zastumotide (GSK2132231A) is being evaluated in a phase III clinical trial in patients with resected stage IIIB/IIIC melanoma. This trial failed to demonstrate a significant prolongation of DFS in patients with positive expression of MAGE-A3 [Melero et al. 2014], but it is ongoing in a subset of patients who are positive for a predictive marker of response [Ulloa-Montoya et al. 2013]. A phase II clinical trial of zastumotide (GSK1572932A) in patients with resected stage IB/II NSCLC exhibited a trend toward positive treatment outcomes compared with placebo [Vansteenkiste et al. 2013]; however, a large phase III study in patients with resected stage IB-IIIA NSCLC failed to meet its primary endpoint of significant prolongation of DFS, resulting in termination of the study [Melero et al. 2014]. Clinical development of zastumotide appears to have been discontinued.

Oncofetal antigens: CEA and 5T4

Oncofetal antigens are so-called because though widely expressed during fetal development, normal expression is generally limited in adults. In cancer, the expression of these antigens becomes upregulated, making them potential targets for immunotherapeutic intervention.

CEA

CEA is a well-known oncofetal antigen normally expressed in the stomach, tongue, esophagus, cervix and prostate in adults, but becomes highly overexpressed in colorectal and gastric cancers [Beauchemin and Arabzadeh, 2013]. Clinically, CEA has been investigated extensively as an immunotherapeutic target for colorectal and various other cancers [Turriziani et al. 2012]. In a phase I/II clinical trial, treatment with an adenoviral gene delivery platform encoding the CEA antigen produced cell-mediated immunity in 61% of patients with advanced CRC and a 48% OS rate at 12 months [Morse et al. 2013a]. A phase II study in CRC patients who were disease-free following metastasectomy and perioperative chemotherapy compared the effectiveness of autologous dendritic cells modified with PANVAC™, a poxvector encoding both CEA and MUC1, to the PANVAC™ poxvector administered in combination with GM-CSF. Survival and recurrence-free survival were similar between the two treatment groups, and vaccinated patients overall experienced superior survival compared with a contemporary group of patients not treated with immunotherapy [Morse et al. 2013b]. In a recently reported phase II trial comparing treatment with PANVAC™ in combination with docetaxel to docetaxel alone in 48 patients with metastatic breast cancer, patients treated with the combination experienced improved PFS compared with docetaxel alone, a result which, while not significant, was suggestive of a clinical benefit [Heery et al. 2015]. Increased CEA expression has been associated with shorter relapse-free survival in breast cancer patients [Saadatmand et al. 2013].

5T4

The oncofetal antigen 5T4 was identified by screening for shared surface molecules in human trophoblasts and human cancer cells [Stern et al. 2014]. A heavily glycosylated, membrane-bound protein, 5T4 is highly expressed in cervical, colorectal, gastric, ovarian, prostate, lung and renal cancers [Southall et al. 1990]. The expression of 5T4 has been associated with epithelial mesenchymal transition (EMT), which is involved in the metastasis of epithelial cancers [Nieto and Cano, 2012]. Three different 5T4-based immunotherapeutic strategies are being clinically evaluated: a vaccine known as TroVax^® (modified vaccinia virus Ankara- MVA), an antibody–superantigen [Staphylococcal Enterotoxin A (SEA)] fusion protein, and an antibody–drug conjugate (ADC) combining a 5T4-specific monoclonal antibody with a tubulin inhibitor.

5T4 vaccine (TroVax®)

Favorable trends toward clinical benefit have been observed in early phase I and phase II clinical trials of the TroVax^® 5T4-MVA vaccine in advanced RCC [Zhang et al. 2012], CRC [Rowe and Cen, 2014], and castration-resistant prostate cancer [Harrop et al. 2013]. To determine whether treatment with TroVax^® can improve survival, a phase III clinical trial in patients with metastatic RCC compared treatment with TroVax^® to standard of care treatment [Amato et al. 2010]. While this trial failed to demonstrate any significant effects of TroVax^® on OS, a subgroup of patients with good prognosis and receiving concurrent IL-2 experienced a significant survival benefit compared with placebo. The patients with the greatest increases in 5T4-specific antibodies also experienced a survival benefit with TroVax^® compared with placebo, which is consistent with a pooled analysis of prior phase I/II TroVax^® studies [Harrop et al. 2010].

5T4 superantigen–antibody fusion protein (naptumomab estafenatox)

The tumor-targeted super-antigen concept employs bacterial superantigens, which are the most potent known activators of T cells, to attract and activate large numbers of T cells to the target [Eisen et al. 2014]. A phase II study of the superantigen-antibody fusion protein targeting 5T4 in RCC showed a significant survival benefit [Shaw et al. 2007], which led to the development of ANYARA (naptumomab estafenatox) [Eisen et al. 2014]. Naptumomab estafenatox has been evaluated in combination with interferon α in a phase II/III clinical trial involving patients with advanced RCC. Although the study failed to meet its primary endpoint, survival benefits were seen in a subgroup of patients with low levels of IL-6 and normal levels of SEA antibodies [Elkord et al. 2015]. The results of this study are still undergoing analysis, and a phase II/III clinical trial of naptumomab estafenatox in combination with a TKI for metastatic RCC is being designed [Stern et al. 2014]. Lastly, promising preclinical activity has been seen with an ADC targeting 5T4 [Sapra et al. 2013], and clinical evaluation is now underway [Stern et al. 2014].

PSA

PSA is a well-known prostate cancer biomarker that is now a target for antigen-specific immunotherapy. An anticancer vaccine known as PROSTVAC^®-VF (PSA-TRICOM; rilimogene galvacirepvec) has been developed that incorporates three co-stimulatory molecules (CD80, CD54 and CD58, collectively referred to as TRICOM) and two recombinant viral vectors encoding PSA transgenes [Singh et al. 2015]. Patients are primed with the vaccinia-based vector and then boosted with a fowlpox vector, both of which are administered with GM-CSF. Early phase I and phase II clinical trials in patients with metastatic castration-resistant prostate cancer (mCRPC) demonstrated that PROSTVAC^®-VF is safe, induces a high rate of immune responses and has survival benefits [DiPaola et al. 2006; Arlen et al. 2007; Gulley et al. 2010]. A double-blind, randomized, controlled phase II clinical trial in patients with mCRPC showed that treatment with PROSTVAC^®-VF significantly improved OS by 8.5 months compared to treatment with control vectors [Kantoff et al. 2010b]. A phase III clinical trial [ClinicalTrials.gov identifier: NCT01322490] in 1200 patients with asymptomatic or minimally symptomatic mCRPC is currently ongoing [Singh et al. 2015].

Survivin

Also known as BIRC5 (baculoviral inhibitor of apoptosis protein repeat-containing 5), survivin is an inhibitor of the intrinsic apoptosis pathway that is widely overexpressed in cancers, making it an attractive target for antigen-specific immunotherapy [Mobahat et al. 2014]. Peptide cancer vaccines targeting survivin have been evaluated in phase I and phase II clinical trials. A phase I study of a multi-epitope anti-survivin peptide vaccine (EMD640744) in patients with advanced solid tumors found an antigen-specific T-cell response in 63% of subjects, and 28% of vaccinated subjects achieved stable disease [Lennerz et al. 2014]. Another phase I study in pediatric brainstem glioma patients using a tripeptide vaccine containing survivin and given in combination with the immunoadjuvant poly-ICLC (polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose) showed evidence of survivin-specific immune responses and clinical benefit [Pollack et al. 2014]. In grade 2 low-grade glioma patients, vaccination with survivin and three other glioma-associated peptides combined with poly-ICLC produced robust T_H1 immune responses [Okada et al. 2015]. The efficacy of another survivin-targeted peptide vaccine in metastatic melanoma patients was evaluated in a phase II clinical trial. Treatment with the vaccine, which contained three survivin peptide epitopes, significantly prolonged OS in patients with antigen-specific T-cell responses [Becker et al. 2012].

IDO1

Upregulation of indolamine-2,3-dioxygenase (IDO1), which catabolizes the essential amino acid tryptophan, is a recently discovered mechanism of tumor cell immune escape. Tryptophan is required for normal T-cell function, and its depletion can lead to immunosuppression [Jiang et al. 2015]. The IDO1 enzyme is overexpressed in various malignancies including breast, NSCLC, prostate and gastric cancers [Uyttenhove et al. 2003]. Two small molecule IDO1 enzyme inhibitors and a peptide-based vaccine are currently being evaluated in clinical trials. Indoximod (1-methly-D-tryptophan) combined with docetaxel was evaluated in a phase I clinical trial in patients with metastatic solid tumors. The treatment was well tolerated with evidence of clinical activity [Soliman et al. 2014]. A phase II trial of this agent in combination with docetaxel as first-line treatment for metastatic breast cancer is ongoing [ClinicalTrials.gov identifier: NCT01792050], in addition to a number of other phase II studies in metastatic melanoma, prostate and pancreatic cancers.

The other small molecule IDO1 inhibitor, INCB024360, is currently being evaluated in combination with ipilimumab in a phase I/II study [ClinicalTrials.gov identifier: NCT02077114 (completed)] in metastatic melanoma [Iversen et al. 2015], a phase I/II study [ClinicalTrials.gov identifier: NCT02318277] of INCB024360 in combination with durvalumab in patients with advanced solid tumors [Ibrahim et al. 2015] and a phase Ib study [ClinicalTrials.gov identifier: NCT02298153] in stage IIIB/IV NSCLC in combination with atezolizumab [Cha et al. 2015]. A peptide vaccine targeting IDO1 was evaluated in a phase I clinical trial in patients with metastatic NSCLC. Median OS was approximately 26 months, and long-lasting disease stabilization was observed in 47% of patients. A currently ongoing phase II study in patients with metastatic melanoma is evaluating the effects of a peptide vaccine containing epitopes to survivin and IDO1 in combination with temozolomide [Iversen et al. 2014].

Discussion

With the recent clinical development and therapeutic successes of immune checkpoint inhibitors targeting the CTLA-4 and PD-1/PD-L1 pathways, such as ipilimumab, pembrolizumab and nivolumab, enthusiasm surrounding anticancer immunotherapy has become intense. However, despite the impressive improvements in clinical outcome seen with these agents, the response rates remain modest, but encouraging. Clearly, we must expand our knowledge about how these agents work and the safest way to administer them in order to improve their efficacy. With respect to antigen-specific immunotherapies, the abundance of tumor antigens that have been identified has allowed for the development of multiple monoclonal antibodies and peptide cancer vaccines targeting these antigens, but the responses to these agents as well remain modest, due in part to mechanisms of tumor evasion and immunosuppression, and the fact that TAA expression profiles are patient-specific. With the availability of checkpoint inhibitors, it is now possible to alter the immunosuppressive tumor microenvironment, which could potentially increase the efficacy of antigen-specific immunotherapies. It is thus becoming quite clear that in order to derive the maximum benefit from these novel immunotherapies, we must learn more about how to best use these agents in combination with chemotherapy and with each other. Numerous clinical trials investigating various combinations of immunotherapies and chemotherapy are already underway.

Another point to consider with the use of cancer vaccines is that while they are not often associated with clinically significant objective responses or improvements in PFS, they have been shown to significantly prolong OS, and thus OS may be the most valid clinical endpoint for assessment of the efficacy of these agents [DeGregorio et al. 2012; Dillman, 2015]. Ultimately, personalized immunotherapy, whereby patients are screened for the expression of tumor antigens and PD-1/PD-L1 so that they can be matched with the appropriate antigen-specific agent, checkpoint inhibitor and chemotherapeutic agent, may be the best means of deriving the maximum therapeutic benefits from these treatments [Kao et al. 2015]. The future of personalized cancer immunotherapy has never been more promising, and the results of ongoing clinical trials are eagerly awaited.

Footnotes

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Conflict of interest statement

The author(s) declare(s) that there is no conflict of interest.

References

Advani

McDonough

Coutre

Wood

Radich

Mims

. (2014) SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. Br J Haematol 165: 504–509.

Agarwal

Saini

Parashar

Verma

Sinha

Jagadish

. (2013) The novel cancer-testis antigen A-kinase anchor protein 4 (AKAP4) is a potential target for immunotherapy of ovarian serous carcinoma. Oncoimmunology 2: e24270.

Advani

(2015) Current status of antibody therapy in ALL. Br J Haematol 168: 471–480.

Akiyama

Komiyama

Miyata

Yagoto

Ashizawa

Iizuka

. (2014) Novel cancer-testis antigen expression on glioma cell lines derived from high-grade glioma patients. Oncol Rep 31: 1683–1690.

Alfonso

Diaz

Hernandez

Perez

Rodriguez

Bitton

. (2002) An anti-idiotype vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients. J Immunol 168: 2523–2529.

Alfonso

Valdes-Zayas

Santiesteban

Flores

Areces

Hernandez

. (2014) A randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients. Clin Cancer Res 20: 3660–3671.

Almeida

Sakabe

deOliveira

Silva

Mundstein

Cohen

. (2009) CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens. Nucleic Acids Res 37: D816–D819.

Amato

Hawkins

Kaufman

Thompson

Tomczak

Szczylik

. (2010) Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study. Clin Cancer Res 16: 5539–5547.

Anderson

(2014) TIM-3: an emerging target in the cancer immunotherapy landscape. Cancer Immunol Res 2: 393–398.

10.

Anderson

Venanzi

Klein

Chen

Berzins

Turley

. (2002) Projection of an immunological self shadow within the thymus by the Aire protein. Science 298: 1395–1401.

11.

Annesley

Brown

(2015) Novel agents for the treatment of childhood acute leukemia. Ther Adv Hematol 6: 61–79.

12.

Apostolopoulos

McKenzie

(1994) Cellular mucins: targets for immunotherapy. Crit Rev Immunol 14: 293–309.

13.

Arlen

Skarupa

Pazdur

Seetharam

Tsang

Grosenbach

. (2007) Clinical safety of a viral vector based prostate cancer vaccine strategy. J Urol 178: 1515–1520.

14.

Armand

Nagler

Weller

Devine

Avigan

Chen

. (2013) Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol 31: 4199–4206.

15.

Atkins

Kudchadkar

Sznol

McDermott

Lotem

Schachter

. (2014) Phase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma. J Clin Oncol 32(Suppl. 5): abstract 9001.

16.

Bagarazzi

Yan

Morrow

Shen

Parker

Lee

. (2012) Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med 4: 155ra138.

17.

Bang

Van Cutsem

Feyereislova

Chung

Shen

Sawaki

. (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376: 687–697.

18.

Beauchemin

Arabzadeh

(2013) Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis. Cancer Metastasis Rev 32: 643–671.

19.

Becker

Andersen

Hofmeister-Muller

Wobser

Frey

Sandig

. (2012) Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma. Cancer Immunol Immunother 61: 2091–2103.

20.

Berger

Sommermeyer

Hudecek

Berger

Balakrishnan

Paszkiewicz

. (2015) Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells. Cancer Immunol Res 3: 206–216.

21.

Bokemeyer

Bondarenko

Makhson

Hartmann

Aparicio

de Braud

. (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27: 663–671.

22.

Bokemeyer

Van Cutsem

Rougier

Ciardiello

Heeger

Schlichting

. (2012) Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 48: 1466–1475.

23.

Bonner

Harari

Giralt

Azarnia

Shin

Cohen

. (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354: 567–578.

24.

Boyerinas

Jochems

Fantini

Heery

Gulley

Tsang

. (2015) Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells. Cancer Immunol Res 3: 1148–1157.

25.

Brahmer

Reckamp

Baas

Crino

Eberhardt

Poddubskaya

. (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373: 123–135.

26.

Brahmer

Tykodi

Chow

Hwu

Topalian

Hwu

. (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366: 2455–2465.

27.

Brayman

Thathiah

Carson

(2004) MUC1: a multifunctional cell surface component of reproductive tissue epithelia. Reprod Biol Endocrinol 2: 4.

28.

Brignone

Gutierrez

Mefti

Brain

Jarcau

Cvitkovic

. (2010) First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity. J Transl Med 8: 71.

29.

Brun

Dalstein

Leveque

Mathevet

Raulic

Baldauf

. (2011) Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy. Am J Obstet Gynecol 204: 169.e1–169.e8.

30.

Butts

Socinski

Mitchell

Thatcher

Havel

Krzakowski

. (2014) Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol 15: 59–68.

31.

Buzzonetti

Fossati

Catzola

Scambia

Fattorossi

Battaglia

(2014) Immunological response induced by abagovomab as a maintenance therapy in patients with epithelial ovarian cancer: relationship with survival - a substudy of the MIMOSA trial. Cancer Immunol Immunother 63: 1037–1045.

32.

Calabro

Ceresoli

di Pietro

Cutaia

Morra

Ibrahim

. (2015) CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy? Cancer Immunol Immunother 64: 105–112.

33.

Calabro

Morra

Fonsatti

Cutaia

Amato

Giannarelli

. (2013) Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol 14: 1104–1111.

34.

Camisaschi

De Filippo

Beretta

Vergani

Villa

Vergani

. (2014) Alternative activation of human plasmacytoid DCs in vitro and in melanoma lesions: involvement of LAG-3. J Invest Dermatol 134: 1893–1902.

35.

Cha

Wallin

Kowanetz

(2015) PD-L1 inhibition with MPDL3280A for solid tumors. Semin Oncol 42: 484–487.

36.

Cheema

Hari-Gupta

Kita

Farrar

Seddon

Corr

. (2014) Expression of the cancer-testis antigen BORIS correlates with prostate cancer. Prostate 74: 164–176.

37.

Chen

Deng

Han

Bai

Liu

. (2014) SPAG9 expression is increased in human prostate cancer and promotes cell motility, invasion and angiogenesis in vitro. Oncol Rep 32: 2533–2540.

38.

Chen

Dawoodji

Tarlton

Gnjatic

Tajar

Karydis

. (2015) NY-ESO-1 specific antibody and cellular responses in melanoma patients primed with NY-ESO-1 protein in ISCOMATRIX and boosted with recombinant NY-ESO-1 fowlpox virus. Int J Cancer 136: E590–E601.

39.

Chen

(2015) Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma. Drug Des Devel Ther 9: 1729–1733.

40.

Chen

Scanlan

Sahin

Tureci

Gure

Tsang

. (1997) A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A 94: 1914–1918.

41.

Cheng

Kananathan

(2012) CIMAvax EGF vaccine for stage IIIb/IV non-small cell lung carcinoma. Hum Vaccin Immunother 8: 1799–1801.

42.

Cheng

Ruan

(2015) Tim-3 and Tim-4 as the potential targets for antitumor therapy. Hum Vaccin Immunother 11: 2458–2462.

43.

Chung

(2015) Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics. J Oncol Pharm Pract. DOI: 10.1177/1078155215577810.

44.

Coosemans

Vergote

Van Gool

(2014) Wilms’ tumor gene 1 immunotherapy in pelvic gynecological malignancies. Expert Rev Clin Immunol 10: 705–711.

45.

Creelan

(2014) Update on immune checkpoint inhibitors in lung cancer. Cancer Control 21: 80–89.

46.

Cunningham

Humblet

Siena

Khayat

Bleiberg

Santoro

. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337–345.

47.

Curigliano

Criscitiello

Esposito

Fumagalli

Gelao

Locatelli

. (2013) Developing an effective breast cancer vaccine: challenges to achieving sterile immunity versus resetting equilibrium. Breast 22(Suppl. 2): S96–S99.

48.

De Pas

Giovannini

Rescigno

Catania

Toffalorio

Spitaleri

. (2012) Vaccines in non-small cell lung cancer: rationale, combination strategies and update on clinical trials. Crit Rev Oncol Hematol 83: 432–443.

49.

DeGregorio

Soe

Wolf

(2014) Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small cell lung cancer (START): a randomized, double-blind, phase III trial. J Thorac Dis 6: 571–573.

50.

DeGregorio

Wurz

Gutierrez

Wolf

(2012) L-BLP25 vaccine plus letrozole for breast cancer: Is translation possible? OncoImmunology 1: 1422–1424.

51.

Derbinski

Gabler

Brors

Tierling

Jonnakuty

Hergenhahn

. (2005) Promiscuous gene expression in thymic epithelial cells is regulated at multiple levels. J Exp Med 202: 33–45.

52.

Di Stasi

Jimenez

Minagawa

Al-Obaidi

Rezvani

(2015) Review of the results of WT1 peptide vaccination strategies for myelodysplastic syndromes and acute myeloid leukemia from nine different studies. Front Immunol 6: 36.

53.

Diaz

Alfonso

Alonso

Saurez

Troche

Catala

. (2003) Immune responses in breast cancer patients immunized with an anti-idiotype antibody mimicking NeuGc-containing gangliosides. Clin Immunol 107: 80–89.

54.

Dillman

(2015) Cancer vaccines: can they improve survival? Cancer Biother Radiopharm 30: 147–151.

55.

DiPaola

Plante

Kaufman

Petrylak

Israeli

Lattime

. (2006) A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer. J Transl Med 4: 1.

56.

Douillard

Siena

Cassidy

Tabernero

Burkes

Barugel

. (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28: 4697–4705.

57.

Eisen

Hedlund

Forsberg

Hawkins

(2014) Naptumomab estafenatox: targeted immunotherapy with a novel immunotoxin. Curr Oncol Rep 16: 370.

58.

Elkord

Burt

Sundstedt

Nordle

Hedlund

Hawkins

(2015) Immunological response and overall survival in a subset of advanced renal cell carcinoma patients from a randomized phase 2/3 study of naptumomab estafenatox plus IFN-alpha versus IFN-alpha. Oncotarget 6: 4428–4439.

59.

Emens

Braiteh

Cassier

Delord

Eder

Fasso

. (2015) Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC) (Abstract 2859). In: Annual Meeting of the American Association for Cancer Research, Philadelphia, PA, 18–22 April.

60.

Endo

de Graaff

Ingram

Lim

Lev

Briaire-de Bruijn

. (2015) NY-ESO-1 (CTAG1B) expression in mesenchymal tumors. Mod Pathol 28: 587–595.

61.

Escudier

Bellmunt

Negrier

Bajetta

Melichar

Bracarda

. (2010) Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 28: 2144–2150.

62.

Escudier

Pluzanska

Koralewski

Ravaud

Bracarda

Szczylik

. (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370: 2103–2111.

63.

Felder

Kapur

Gonzalez-Bosquet

Horibata

Heintz

Albrecht

. (2014) MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress. Mol Cancer 13: 129.

64.

Ferrara

Hillan

Gerber

Novotny

(2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3: 391–400.

65.

Foley

(1953) Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin. Cancer Res 13: 835–837.

66.

Fourcade

Sun

Pagliano

Chauvin

Sander

Janjic

. (2014) PD-1 and TIM-3 regulate the expansion of tumor antigen-specific CD8+ T cells induced by melanoma vaccines. Cancer Res 74: 1045–1055.

67.

Friedman

Prados

Wen

Mikkelsen

Schiff

Abrey

. (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27: 4733–4740.

68.

Fuchs

Tomasek

Yong

Dumitru

Passalacqua

Goswami

. (2014) Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383: 31–39.

69.

Galluzzi

Vacchelli

Bravo-San Pedro

Buque

Senovilla

Baracco

. (2014) Classification of current anticancer immunotherapies. Oncotarget 5: 12472–12508.

70.

Gao

Zhu

Huang

Zhang

Wang

. (2012) TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression. PLoS One 7: e30676.

71.

Garg

Chaurasiya

Rana

Jagadish

Kanojia

Dudha

. (2007) Sperm-associated antigen 9, a novel cancer testis antigen, is a potential target for immunotherapy in epithelial ovarian cancer. Clin Cancer Res 13: 1421–1428.

72.

Garon

Ciuleanu

Arrieta

Prabhash

Syrigos

Goksel

. (2014) Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 384: 665–673.

73.

Garon

Rizvi

Hui

Leighl

Balmanoukian

Eder

. (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372: 2018–2028.

74.

Ghadban

Perez

Vashist

Bockhorn

Koenig

El Gammal

. (2014) Expression of cancer testis antigens CT10 (MAGE-C2) and GAGE in gastrointestinal stromal tumors. Eur J Surg Oncol 40: 1307–1312.

75.

Giantonio

Catalano

Meropol

O’Dwyer

Mitchell

Alberts

. (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25: 1539–1544.

76.

Goldberg

Drake

(2011) LAG-3 in Cancer Immunotherapy. Curr Top Microbiol Immunol 344: 269–278.

77.

Gonzalez

Crombet

Neninger

Viada

Lage

(2007) Therapeutic vaccination with epidermal growth factor (EGF) in advanced lung cancer: analysis of pooled data from three clinical trials. Hum Vaccin 3: 8–13.

78.

Gotter

Brors

Hergenhahn

Kyewski

(2004) Medullary epithelial cells of the human thymus express a highly diverse selection of tissue-specific genes colocalized in chromosomal clusters. J Exp Med 199: 155–166.

79.

GuhaThakurta

Sheikh

Fan

Kandadi

Meagher

Hall

. (2015) Humoral immune response against nontargeted tumor antigens after treatment with sipuleucel-T and its association with improved clinical outcome. Clin Cancer Res 21: 3619–3630.

80.

Gulley

Arlen

Madan

Tsang

Pazdur

Skarupa

. (2010) Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother 59: 663–674.

81.

Gulley

Spigel

Kelly

Chandler

Rajan

Hassan

. (2015) Avelumab (MSB0010718C), an anti-PD-L1 antibody, in advanced NSCLC patients: A phase Ib, open-label expansion trial in patients progressing after platinum-based chemotherapy. J Clin Oncol 33(Suppl.): abstract 8034.

82.

Hamid

Robert

Daud

Hodi

Hwu

Kefford

. (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369: 134–144.

83.

Harrop

Chu

Gabrail

Srinivas

Blount

Ferrari

(2013) Vaccination of castration-resistant prostate cancer patients with TroVax (MVA-5T4) in combination with docetaxel: a randomized phase II trial. Cancer Immunol Immunother 62: 1511–1520.

84.

Harrop

Shingler

Kelleher

de Belin

Treasure

(2010) Cross-trial analysis of immunologic and clinical data resulting from phase I and II trials of MVA-5T4 (TroVax) in colorectal, renal, and prostate cancer patients. J Immunother 33: 999–1005.

85.

Hay

Sult

Huang

Hammond

Mulgrew

McGlinchey

. (2015) MEDI9447: Enhancing anti-tumor immunity by targeting CD73 in the tumor microenvironment. Cancer Res 75(Suppl. 15): abstract 285.

86.

Liu

Xue

Liang

(2014) Expression of cancer-testis antigen in multiple myeloma. J Huazhong Univ Sci Technolog Med Sci 34: 181–185.

87.

Heery

Ibrahim

Arlen

Mohebtash

Murray

Koenig

. (2015) Docetaxel alone or in combination with a therapeutic cancer vaccine (PANVAC) in patients with metastatic breast cancer: A randomized clinical trial. JAMA Oncol. DOI: 10.1001/jamaoncol.2015.2736.

88.

Herbst

Soria

Kowanetz

Fine

Hamid

Gordon

. (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515: 563–567.

89.

Hodi

Lawrence

Lezcano

Zhou

Sasada

. (2014) Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res 2: 632–642.

90.

Hodi

O’Day

McDermott

Weber

Sosman

Haanen

. (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711–723.

91.

Hoffman

Gore

(2014) Blinatumomab, a bi-specific anti-CD19/CD3 BiTE((R)) antibody for the treatment of acute lymphoblastic leukemia: perspectives and current pediatric applications. Front Oncol 4: 63.

92.

Hojjat-Farsangi

Moshfegh

Daneshmanesh

Khan

Mikaelsson

Osterborg

. (2014) The receptor tyrosine kinase ROR1–an oncofetal antigen for targeted cancer therapy. Semin Cancer Biol 29: 21–31.

93.

Homet Moreno

Parisi

Robert

Ribas

(2015) Anti-PD-1 therapy in melanoma. Semin Oncol 42: 466–473.

94.

Horn

Spigel

Gettinger

Antonia

Gordon

Herbst

. (2015) Clinical activity, safety and predictive biomarkers of the engineered antibody MPDL3280A (anti-PD-L1) in non-small cell lung cancer (NSCLC): update from a phase Ia study. J Clin Oncol 33(suppl.): abstract 8029.

95.

Huang

Workman

Flies

Pan

Marson

Zhou

. (2004) Role of LAG-3 in regulatory T cells. Immunity 21: 503–513.

96.

Hunder

Wallen

Cao

Hendricks

Reilly

Rodmyre

. (2008) Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 358: 2698–2703.

97.

Hurwitz

Fehrenbacher

Novotny

Cartwright

Hainsworth

Heim

. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335–2342.

98.

Hynes

Lane

(2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5: 341–354.

99.

Ibrahim

Murray

Zhou

Mittendorf

Sample

Tautchin

. (2013) Survival advantage in patients with metastatic breast cancer receiving endocrine therapy plus sialyl Tn-KLH vaccine: post hoc analysis of a large randomized trial. J Cancer 4: 577–584.

100.

Ibrahim

Stewart

Shalabi

(2015) PD-L1 blockade for cancer treatment: MEDI4736. Semin Oncol 42: 474–483.

101.

Isfort

Keller-v Amsberg

Schafhausen

Koschmieder

Brummendorf

(2014) Bosutinib: a novel second-generation tyrosine kinase inhibitor. Recent Results Cancer Res 201: 81–97.

102.

Ishikawa

Imano

Shiraishi

Yasuda

Peng

Shinkai

. (2014) Phase I clinical trial of vaccination with LY6K-derived peptide in patients with advanced gastric cancer. Gastric Cancer 17: 173–180.

103.

Iversen

Andersen

Svane

(2015) The targeting of indoleamine 2,3 dioxygenase -mediated immune escape in cancer. Basic Clin Pharmacol Toxicol 116: 19–24.

104.

Iversen

Engell-Noerregaard

Ellebaek

Andersen

Larsen

Bjoern

. (2014) Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase. Clin Cancer Res 20: 221–232.

105.

Iwai

Ishida

Tanaka

Okazaki

Honjo

Minato

(2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 99: 12293–12297.

106.

Jiang

Sun

Yin

Feng

Sun

(2015) Research progress of indoleamine 2,3-dioxygenase inhibitors. Future Med Chem 7: 185–201.

107.

Jing

Gershan

Weber

Tlomak

McOlash

Sabatos-Peyton

. (2015) Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma. J Immunother Cancer 3: 2.

108.

Jonker

O’Callaghan

Karapetis

Zalcberg

. (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357: 2040–2048.

109.

Jungbluth

Chen

Stockert

Busam

Kolb

Iversen

. (2001) Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer 92: 856–860.

110.

Kanojia

Garg

Gupta

Suri

(2011) Sperm-associated antigen 9 is a novel biomarker for colorectal cancer and is involved in tumor growth and tumorigenicity. Am J Pathol 178: 1009–1020.

111.

Kantoff

Higano

Shore

Berger

Small

Penson

. (2010a) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363: 411–422.

112.

Kantoff

Schuetz

Blumenstein

Glode

Bilhartz

Wyand

. (2010b) Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 28: 1099–1105.

113.

Kao

Wurz

Lin

Vang

Griffey

Wolf

. (2015) Assessing the effects of concurrent versus sequential cisplatin/radiotherapy on immune status in lung tumor-bearing C57BL/6 mice. Cancer Immunol Res 3: 741–750.

114.

Kao

Wurz

Monjazeb

Vang

Cadman

Griffey

. (2014) Antitumor effects of cisplatin combined with tecemotide immunotherapy in a human MUC1 transgenic lung cancer mouse model. Cancer Immunol Res 2: 581–589.

115.

Kaplan

Shankaran

Dighe

Stockert

Aguet

Old

. (1998) Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A 95: 7556–7561.

116.

Kaufman

Hamid

D’Angelo

Yuan

Chin

Bhatia

. (2015) A phase II, open-label, multicenter trial to investigate the clinical activity and safety of avelumab (MSB0010718C) in patients with metastatic Merkel cell carcinoma. J Clin Oncol 33(Suppl.): abstract TPS9086.

117.

Kawai

Enomoto

Morikawa

Matsushita

Kume

Fukayama

. (2014) High expression of heat shock protein 105 predicts a favorable prognosis for patients with urinary bladder cancer treated with radical cystectomy. Mol Clin Oncol 2: 38–42.

118.

Kelly

Patel

Infante

Iannotti

Nikolinakos

Leach

. (2015) Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic or locally advanced solid tumors: assessment of safety and tolerability in a phase I, open-label expansion study. J Clin Oncol 33(Suppl.): abstract 3044.

119.

Kenter

Welters

Valentijn

Lowik

Berends-van der Meer

Vloon

. (2009) Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 361: 1838–1847.

120.

Kimura

Finn

(2013) MUC1 immunotherapy is here to stay. Expert Opin Biol Ther 13: 35–49.

121.

Kirkwood

Butterfield

Tarhini

Zarour

Kalinski

Ferrone

(2012) Immunotherapy of cancer in 2012. CA Cancer J Clin 62: 309–335.

122.

Klein

Sjogren

Klein

Hellstrom

(1960) Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res 20: 1561–1572.

123.

Klein

Davis

McArthur

Chen

Haydon

Parente

. (2015) Low-dose cyclophosphamide enhances antigen-specific CD4(+) T cell responses to NY-ESO-1/ISCOMATRIX vaccine in patients with advanced melanoma. Cancer Immunol Immunother 64: 507–518.

124.

Kohrt

Houot

Marabelle

Cho

Osman

Goldstein

. (2012) Combination strategies to enhance antitumor ADCC. Immunotherapy 4: 511–527.

125.

Kohrt

Thielens

Marabelle

Sagiv-Barfi

Sola

Chanuc

. (2014) Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood 123: 678–686.

126.

Kruit

Suciu

Dreno

Mortier

Robert

Chiarion-Sileni

. (2013) Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. J Clin Oncol 31: 2413–2420.

127.

Kular

Yehiely

Deiss

(2010) Rational drug design: a GAGE derived peptide kills tumor cells. Cancer Biol Ther 9: 825–831.

128.

Larkin

Chiarion-Sileni

Gonzalez

Grob

Cowey

Lao

. (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373: 23–34.

129.

Le Mercier

Chen

Lines

Day

Sergent

. (2014) VISTA Regulates the development of protective antitumor immunity. Cancer Res 74: 1933–1944.

130.

Lee

Kim

Cho

Kim

Park

. (2014) Expression of the brother of the regulator of imprinted sites gene in the sputum of patients with lung cancer. Korean J Thorac Cardiovasc Surg 47: 378–383.

131.

Lee

Chow

(2014) A new addition to the PD-1 checkpoint inhibitors for non-small cell lung cancer-the anti-PDL1 antibody-MEDI4736. Transl Lung Cancer Res 3: 408–410.

132.

Lennerz

Gross

Gallerani

Sessa

Mach

Boehm

. (2014) Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors. Cancer Immunol Immunother 63: 381–394.

133.

Lindauer

Hochhaus

(2014) Dasatinib. Recent Results Cancer Res 201: 27–65.

134.

Lines

Pantazi

Mak

Sempere

Wang

O’Connell

. (2014a) VISTA is an immune checkpoint molecule for human T cells. Cancer Res 74: 1924–1932.

135.

Lines

Sempere

Broughton

Wang

Noelle

(2014b) VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy. Cancer Immunol Res 2: 510–517.

136.

Liu

Yuan

Chen

Putra

Suriawinata

Schenk

. (2015a) Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses. Proc Natl Acad Sci U S A 112: 6682–6687.

137.

Liu

Powderly

Camidge

Ready

Heist

Hodi

. (2015b) Safety and efficacy of MPDL3280A (anti-PD-L1) in combination with platinum-based doublet chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 33(Suppl.): abstract 8030.

138.

Loke

Khan

Wilson

Craddock

Wheatley

(2015) Mylotarg has potent anti-leukaemic effect: a systematic review and meta-analysis of anti-CD33 antibody treatment in acute myeloid leukaemia. Ann Hematol 94: 361–373.

139.

Lee-Gabel

Nadeau

Ferencz

Soefje

(2014) Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy. J Oncol Pharm Pract. DOI: 10.1177/1078155214538087.

140.

Manzoni

Rovati

Ronzoni

Loupakis

Mariucci

Ricci

. (2010) Immunological effects of bevacizumab-based treatment in metastatic colorectal cancer. Oncology 79: 187–196.

141.

Melero

Gaudernack

Gerritsen

Huber

Parmiani

Scholl

. (2014) Therapeutic vaccines for cancer: an overview of clinical trials. Nat Rev Clin Oncol 11: 509–524.

142.

Miles

Roche

Martin

Perren

Cameron

Glaspy

. (2011) Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer. Oncologist 16: 1092–1100.

143.

Miller

Wang

Gralow

Dickler

Cobleigh

Perez

. (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357: 2666–2676.

144.

Mirandola

Figueroa

Phan

Grizzi

Kim

Rahman

. (2015) Novel antigens in non-small cell lung cancer: SP17, AKAP4, and PTTG1 are potential immunotherapeutic targets. Oncotarget 6: 2812–2826.

145.

Mitchell

Thatcher

Socinski

Wasilewska-Tesluk

Horwood

Szczesna

. (2015) Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses. Ann Oncol 26: 1134–1142.

146.

Miyazaki

Ikeda

Horie-Inoue

Kondo

Takahashi

Inoue

(2014) EBAG9 modulates host immune defense against tumor formation and metastasis by regulating cytotoxic activity of T lymphocytes. Oncogenesis 3: e126.

147.

Mobahat

Narendran

Riabowol

(2014) Survivin as a preferential target for cancer therapy. Int J Mol Sci 15: 2494–2516.

148.

Morgan

Chinnasamy

Abate-Daga

Gros

Robbins

Zheng

. (2013) Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother 36: 133–151.

149.

Morse

Chaudhry

Gabitzsch

Hobeika

Osada

Clay

. (2013a) Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients. Cancer Immunol Immunother 62: 1293–1301.

150.

Morse

Niedzwiecki

Marshall

Garrett

Chang

Aklilu

. (2013b) A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer. Ann Surg 258: 879–886.

151.

Muhlbauer

Fleck

Schutz

Weiss

Froh

Blank

. (2006) PD-L1 is induced in hepatocytes by viral infection and by interferon-alpha and -gamma and mediates T cell apoptosis. J Hepatol 45: 520–528.

152.

Mullard

(2013) New checkpoint inhibitors ride the immunotherapy tsunami. Nat Rev Drug Discov 12: 489–492.

153.

Nauts

Fowler

Bogatko

(1953) A review of the influence of bacterial infection and of bacterial products (Coley’s toxins) on malignant tumors in man; a critical analysis of 30 inoperable cases treated by Coley’s mixed toxins, in which diagnosis was confirmed by microscopic examination selected for special study. Acta Med Scand Suppl 276: 1–103.

154.

Neninger Vinageras

de la Torre

Osorio Rodriguez

Catala Ferrer

Bravo

Mendoza del Pino

. (2008) Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer. J Clin Oncol 26: 1452–1458.

155.

Ngiow

von Scheidt

Akiba

Yagita

Teng

Smyth

(2011) Anti-TIM3 antibody promotes T cell IFN-gamma-mediated antitumor immunity and suppresses established tumors. Cancer Res 71: 3540–3551.

156.

Nguyen

Ohashi

(2015) Clinical blockade of PD1 and LAG3–potential mechanisms of action. Nat Rev Immunol 15: 45–56.

157.

Nicholaou

Ebert

Davis

Robson

Klein

Maraskovsky

. (2006) Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1. Immunol Cell Biol 84: 303–317.

158.

Nicholaou

Ebert

Davis

McArthur

Jackson

Dimopoulos

. (2009) Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma. Clin Cancer Res 15: 2166–2173.

159.

Nieto

Cano

(2012) The epithelial-mesenchymal transition under control: global programs to regulate epithelial plasticity. Semin Cancer Biol 22: 361–368.

160.

O’Sullivan

Connolly

(2014) Pertuzumab and its accelerated approval: evolving treatment paradigms and new challenges in the management of HER2-positive breast cancer. Oncology (Williston Park) 28: 186–194, 196.

161.

Odunsi

Matsuzaki

Karbach

Neumann

Mhawech-Fauceglia

Miller

. (2012) Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proc Natl Acad Sci U S A 109: 5797–5802.

162.

Ofuji

Tada

Yoshikawa

Shimomura

Yoshimura

Saito

. (2015) A peptide antigen derived from EGFR T790M is immunogenic in nonsmall cell lung cancer. Int J Oncol 46: 497–504.

163.

Okabayashi

Fujita

Miyazaki

Okada

Iwata

Hirao

. (2012) Cancer-testis antigen BORIS is a novel prognostic marker for patients with esophageal cancer. Cancer Sci 103: 1617–1624.

164.

Okada

Butterfield

Hamilton

Hoji

Sakaki

Ahn

. (2015) Induction of robust type-I CD8+ T-cell responses in WHO grade 2 low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC. Clin Cancer Res 21: 286–294.

165.

Ostendorf

le Coutre

Kim

Quintas-Cardama

(2014) Nilotinib. Recent Results Cancer Res 201: 67–80.

166.

Pao

Miller

Politi

Riely

Somwar

Zakowski

. (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2: e73.

167.

Paz-Ares

Mezger

Ciuleanu

Fischer

von Pawel

Provencio

. (2015) Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study. Lancet Oncol 16: 328–337.

168.

Perez

Romond

Suman

Jeong

Davidson

Geyer

Jr. . (2011) Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 29: 3366–3373.

169.

Perez

Romond

Suman

Jeong

Sledge

Geyer

Jr. . (2014) Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol 32: 3744–3752.

170.

Petrylak

Powles

Bellmunt

Braiteh

Loriot

Zambrano

. (2015) A phase Ia study of MPDL3280A (anti-PD-L1): updated response and survival data in urothelial bladder cancer (UBC). J Clin Oncol 33(Suppl.): abstract 4501.

171.

Pinna

(2014) Adenosine A2A receptor antagonists in Parkinson’s disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued. CNS Drugs 28: 455–474.

172.

Planchard

Shtivelband

Shi

Ibrahim

Ballas

Sorio

. (2015) A phase III study of MEDI4736 (M), an anti-PD-L1 antibody, in monotherapy or in combination with tremelimumab (T), versus standard of care (SOC) in patients (pts) with advanced non-small cell lung cancer (NSCLC) who have received at least two prior systemic treatment regimens (ARCTIC). J Clin Oncol 33(Suppl.): abstract TPS8104.

173.

Pollack

Jakacki

Butterfield

Hamilton

Panigrahy

Potter

. (2014) Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem and nonbrainstem gliomas. J Clin Oncol 32: 2050–2058.

174.

Postow

Chesney

Pavlick

Robert

Grossmann

McDermott

. (2015) Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372: 2006–2017.

175.

Powles

Eder

Fine

Braiteh

Loriot

Cruz

. (2014) MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515: 558–562.

176.

Prehn

Main

(1957) Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst 18: 769–778.

177.

Price

Peeters

Kim

Cascinu

Ruff

. (2014) Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol 15: 569–579.

178.

Pujade-Lauraine

Hilpert

Weber

Reuss

Poveda

Kristensen

. (2014) Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol 32: 1302–1308.

179.

Pujol

Pirker

Lynch

Butts

Rosell

Shepherd

. (2014) Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer. Lung Cancer 83: 211–218.

180.

Raetz

Cairo

Borowitz

Blaney

Krailo

Leil

. (2008) Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children’s Oncology Group Pilot Study. J Clin Oncol 26: 3756–3762.

181.

Raetz

Cairo

Borowitz

Devidas

Reid

. (2015) Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): phase II results from Children’s Oncology Group (COG) study ADVL04P2. Pediatr Blood Cancer 62: 1171–1175.

182.

Reardon

Dietrich

Kaley

Gan

Dunn

Cloughesy

. (2015) Phase II study to evaluate the clinical efficacy and safety of MEDI4736 in patients with glioblastoma (GBM). J Clin Oncol 33(Suppl.): abstract TPS2077.

183.

Reinhard

Yousef

Luetkens

Fehse

Berdien

Kroger

. (2014) Cancer-testis antigen MAGE-C2/CT10 induces spontaneous CD4+ and CD8+ T-cell responses in multiple myeloma patients. Blood Cancer J 4: e212.

184.

Ribas

Kefford

Marshall

Punt

Haanen

Marmol

. (2013) Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 31: 616–622.

185.

Robbins

Morgan

Feldman

Yang

Sherry

Dudley

. (2011) Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 29: 917–924.

186.

Robert

Long

Brady

Dutriaux

Maio

Mortier

. (2015a) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372: 320–330.

187.

Robert

Ribas

Wolchok

Hodi

Hamid

Kefford

. (2014) Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 384: 1109–1117.

188.

Robert

Schachter

Long

Arance

Grob

Mortier

. (2015b) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372: 2521–2532.

189.

Robert

Thomas

Bondarenko

O’Day

Weber

Garbe

. (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364: 2517–2526.

190.

Romano

Michielin

Voelter

Laurent

Bichat

Stravodimou

. (2014) MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a phase I trial. J Transl Med 12: 97.

191.

Romond

Perez

Bryant

Suman

Geyer

Jr. Davidson

. (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673–1684.

192.

Rosenberg

(2001) Progress in human tumour immunology and immunotherapy. Nature 411: 380–384.

193.

Rowe

Cen

(2014) TroVax in colorectal cancer. Hum Vaccin Immunother 10: 3196–3200.

194.

Ruiz

Hunis

Raez

(2014) Immunotherapeutic agents in non-small-cell lung cancer finally coming to the front lines. Curr Oncol Rep 16: 400.

195.

Saadatmand

de Kruijf

Sajet

Dekker-Ensink

van Nes

Putter

. (2013) Expression of cell adhesion molecules and prognosis in breast cancer. Br J Surg 100: 252–260.

196.

Sakuishi

Apetoh

Sullivan

Blazar

Kuchroo

Anderson

(2010) Targeting tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 207: 2187–2194.

197.

Saltz

Meropol

Loehrer

Needle

Sr. Kopit

Mayer

(2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22: 1201–1208.

198.

Sandler

Gray

Perry

Brahmer

Schiller

Dowlati

. (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355: 2542–2550.

199.

Sapra

Damelin

Dijoseph

Marquette

Geles

Golas

. (2013) Long-term tumor regression induced by an antibody–drug conjugate that targets 5T4, an oncofetal antigen expressed on tumor-initiating cells. Mol Cancer Ther 12: 38–47.

200.

Savage

Leventhal

Malchow

(2014) Shaping the repertoire of tumor-infiltrating effector and regulatory T cells. Immunol Rev 259: 245–258.

201.

Sawada

Komori

Tsunoda

Shimomura

Takahashi

Baba

. (2014) Identification of HLA-A2 or HLA-A24-restricted CTL epitopes for potential HSP105-targeted immunotherapy in colorectal cancer. Oncol Rep 31: 1051–1058.

202.

Scagliotti

Novello

Schiller

Hirsh

Sequist

Soria

. (2012) Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer. Clin Lung Cancer 13: 391–395.

203.

Schreiber

Old

Smyth

(2011) Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 331: 1565–1570.

204.

Schumacher

Bunse

Pusch

Sahm

Wiestler

Quandt

. (2014) A vaccine targeting mutant IDH1 induces antitumour immunity. Nature 512: 324–327.

205.

Schwartzentruber

Lawson

Richards

Conry

Miller

Treisman

. (2011) gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 364: 2119–2127.

206.

Scott

(2015) Nivolumab: a review in advanced melanoma. Drugs 75: 1413–1424.

207.

Seimetz

(2011) Novel monoclonal antibodies for cancer treatment: the trifunctional antibody catumaxomab (removab). J Cancer 2: 309–316.

208.

Shabani

Naseri

Shokri

(2015) Receptor tyrosine kinase-like orphan receptor 1: a novel target for cancer immunotherapy. Expert Opin Ther Targets 19: 941–955.

209.

Shankaran

Ikeda

Bruce

White

Swanson

Old

. (2001) IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410: 1107–1111.

210.

Shaw

Connolly

Patel

Kilany

Hedlund

Nordle

. (2007) A phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma. Br J Cancer 96: 567–574.

211.

Shore

(2014) PROSTVAC(R) targeted immunotherapy candidate for prostate cancer. Immunotherapy 6: 235–247.

212.

Sierro

Romero

Speiser

(2011) The CD4-like molecule LAG-3, biology and therapeutic applications. Expert Opin Ther Targets 15: 91–101.

213.

Singh

Pal

Alex

Agarwal

(2015) Development of PROSTVAC immunotherapy in prostate cancer. Future Oncol 11: 2137–2148.

214.

Skoetz

Bauer

Elter

Monsef

Roloff

Hallek

. (2012) Alemtuzumab for patients with chronic lymphocytic leukaemia. Cochrane Database Syst Rev 2: CD008078.

215.

Slamon

Clark

Wong

Levin

Ullrich

McGuire

(1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177–182.

216.

Slamon

Godolphin

Jones

Holt

Wong

Keith

. (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707–712.

217.

Slamon

Leyland-Jones

Shak

Fuchs

Paton

Bajamonde

. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783–792.

218.

Sliwkowski

Mellman

(2013) Antibody therapeutics in cancer. Science 341: 1192–1198.

219.

Smith

Cronk

Lang

McNeel

(2011) Expression and immunotherapeutic targeting of the SSX family of cancer-testis antigens in prostate cancer. Cancer Res 71: 6785–6795.

220.

Sobrero

Maurel

Fehrenbacher

Scheithauer

Abubakr

Lutz

. (2008) EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 26: 2311–2319.

221.

Soliman

Jackson

Neuger

Dees

Harvey

Han

. (2014) A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors. Oncotarget 5: 8136–8146.

222.

Southall

Boxer

Bagshawe

Hole

Bromley

Stern

(1990) Immunohistological distribution of 5T4 antigen in normal and malignant tissues. Br J Cancer 61: 89–95.

223.

Spigel

Chaft

Gettinger

Chao

Dirix

Schmid

. (2015) Clinical activity and safety from a phase II study (FIR) of MPDL3280A (anti-PD-L1) in PD-L1-selected patients with non-small cell lung cancer (NSCLC). J Clin Oncol 33(Suppl.): abstract 8028.

224.

Spigel

Ervin

Ramlau

Daniel

Goldschmidt

Jr. Blumenschein

Jr. . (2013) Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 31: 4105–4114.

225.

Spira

Park

Mazieres

Vansteenkiste

Rittmeyer

Ballinger

. (2015) Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A versus docetaxel in 2L/3L NSCLC (POPLAR). J Clin Oncol 33(Suppl.): abstract 8010.

226.

Staff

Mozaffari

Frodin

Mellstedt

Liljefors

(2014) Telomerase (GV1001) vaccination together with gemcitabine in advanced pancreatic cancer patients. Int J Oncol 45: 1293–1303.

227.

Stagg

Loi

Divisekera

Ngiow

Duret

Yagita

. (2011) Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci U S A 108: 7142–7147.

228.

Stern

Brazzatti

Sawan

McGinn

(2014) Understanding and exploiting 5T4 oncofoetal glycoprotein expression. Semin Cancer Biol 29: 13–20.

229.

Stinchcombe

(2014) Novel agents in development for advanced non-small cell lung cancer. Ther Adv Med Oncol 6: 240–253.

230.

Sunshine

Taube

(2015) PD-1/PD-L1 inhibitors. Curr Opin Pharmacol 23: 32–38.

231.

Suzuki

Cheung

(2015) Disialoganglioside GD2 as a therapeutic target for human diseases. Expert Opin Ther Targets 19: 349–362.

232.

Swaika

Hammond

Joseph

(2015) Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy. Mol Immunol 67: 4–17.

233.

Szabo

(2003) MUC1 expression in lung cancer. Methods Mol Med 74: 251–258.

234.

Tarhini

Leng

Moschos

Yin

Sander

Lin

. (2012) Safety and immunogenicity of vaccination with MART-1 (26–35, 27L), gp100 (209–217, 210M), and tyrosinase (368–376, 370D) in adjuvant with PF-3512676 and GM-CSF in metastatic melanoma. J Immunother 35: 359–366.

235.

Terme

Pernot

Marcheteau

Sandoval

Benhamouda

Colussi

. (2013) VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res 73: 539–549.

236.

Tewari

Sill

Long

3rd Penson

Huang

Ramondetta

. (2014) Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 370: 734–743.

237.

Thatcher

Hirsch

Luft

Szczesna

Ciuleanu

Dediu

. (2015) Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol 16: 763–774.

238.

Topalian

Hodi

Brahmer

Gettinger

Smith

McDermott

. (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366: 2443–2454.

239.

Topalian

Sznol

McDermott

Kluger

Carvajal

Sharfman

. (2014) Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32: 1020–1030.

240.

Torres

Chakraborty

Souchek

Batra

(2012) Mucin-based targeted pancreatic cancer therapy. Curr Pharm Des 18: 2472–2481.

241.

Turriziani

Fantini

Benvenuto

Izzi

Masuelli

Sacchetti

. (2012) Carcinoembryonic antigen (CEA)-based cancer vaccines: recent patents and antitumor effects from experimental models to clinical trials. Recent Pat Anticancer Drug Discov 7: 265–296.

242.

Ulloa-Montoya

Louahed

Dizier

Gruselle

Spiessens

Lehmann

. (2013) Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. J Clin Oncol 31: 2388–2395.

243.

Uyttenhove

Pilotte

Theate

Stroobant

Colau

Parmentier

. (2003) Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 9: 1269–1274.

244.

Vacchelli

Aranda

Eggermont

Galon

Sautes-Fridman

Zitvogel

. (2014) Trial watch: tumor-targeting monoclonal antibodies in cancer therapy. Oncoimmunology 3: e27048.

245.

Van Cutsem

Kohne

Hitre

Zaluski

Chang Chien

Makhson

. (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360: 1408–1417.

246.

Van Cutsem

Peeters

Siena

Humblet

Hendlisz

Neyns

. (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25: 1658–1664.

247.

van der Bruggen

Traversari

Chomez

Lurquin

De Plaen

Van den Eynde

. (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643–1647.

248.

Vansteenkiste

Zielinski

Linder

Dahabreh

Gonzalez

Malinowski

. (2013) Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. J Clin Oncol 31: 2396–2403.

249.

Veillette

Guo

(2013) CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma. Crit Rev Oncol Hematol 88: 168–177.

250.

Vermorken

Mesia

Rivera

Remenar

Kawecki

Rottey

. (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359: 1116–1127.

251.

Vermorken

Trigo

Hitt

Koralewski

Diaz-Rubio

Rolland

. (2007) Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 25: 2171–2177.

252.

Vigneron

Stroobant

Van den Eynde

van der Bruggen

(2013) Database of T cell-defined human tumor antigens: the 2013 update. Cancer Immun 13: 15.

253.

Vlad

Kettel

Alajez

Carlos

Finn

(2004) MUC1 immunobiology: from discovery to clinical applications. Adv Immunol 82: 249–293.

254.

Waller

(2014) Imatinib mesylate. Recent Results Cancer Res 201: 1–25.

255.

Wang

Rubinstein

Lines

Wasiuk

Ahonen

Guo

. (2011) VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J Exp Med 208: 577–592.

256.

Wang

Dong

Miao

Lin

Wang

(2013) Clinical significance and biological roles of SPAG9 overexpression in non-small cell lung cancer. Lung Cancer 81: 266–272.

257.

Wehrle

Pahl

von Bubnoff

(2014) Ponatinib: a third-generation inhibitor for the treatment of CML. Recent Results Cancer Res 201: 99–107.

258.

Weiner

Surana

Wang

(2010) Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 10: 317–327.

259.

Whitehurst

(2014) Cause and consequence of cancer/testis antigen activation in cancer. Annu Rev Pharmacol Toxicol 54: 251–272.

260.

Wilke

Muro

Van Cutsem

Bodoky

Shimada

. (2014) Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 15: 1224–1235.

261.

Wei

Meng

Chen

Gao

Zhang

. (2009) Identification of an HLA-A*0201-restrictive CTL epitope from MUC4 for applicable vaccine therapy. Immunopharmacol Immunotoxicol 31: 468–476.

262.

Wurz

Kao

Wolf

DeGregorio

(2014) Tecemotide: an antigen-specific cancer immunotherapy. Hum Vaccin Immunother 10: 3383–3393.

263.

Xie

Wang

(2015) XAGE-1b Cancer/Testis Antigen Is a Potential Target for Immunotherapy in Prostate Cancer. Urol Int 94: 354–362.

264.

Yamada

Azuma

Muta

Kim

Sugawara

Zhang

. (2013) EGFR T790M mutation as a possible target for immunotherapy; identification of HLA-A*0201-restricted T cell epitopes derived from the EGFR T790M mutation. PLoS One 8: e78389.

265.

Yang

Grote

Ziesmer

Niki

Hirashima

Novak

. (2012) IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma. J Clin Invest 122: 1271–1282.

266.

Yonezawa

Dutt

Chester

Kim

Kohrt

(2015) Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy. Clin Cancer Res 21: 3113–3120.

267.

Yoshitake

Fukuma

Yuno

Hirayama

Nakayama

Tanaka

. (2015) Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients revealed induction of immune responses and improved OS. Clin Cancer Res 21: 312–321.

268.

Zappasodi

Bongarzone

Ghedini

Castagnoli

Cabras

Messina

. (2011) Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic target. Blood 118: 4421–4430.

269.

Zaravinos

(2014) An updated overview of HPV-associated head and neck carcinomas. Oncotarget 5: 3956–3969.

270.

Zhang

Chen

Song

Wen

Zhang

. (2013) Cancer/testis antigen HCA587-derived long peptide vaccine generates potent immunologic responses and antitumor effects in mouse model. Oncol Res 21: 193–200.

271.

Zhang

Shen

Luo

Fan

. (2014) Overexpression of MAGE-D4 in colorectal cancer is a potentially prognostic biomarker and immunotherapy target. Int J Clin Exp Pathol 7: 3918–3927.

272.

Zhang

Bines

Ruby

Kaufman

(2012) TroVax((R)) vaccine therapy for renal cell carcinoma. Immunotherapy 4: 27–42.

273.

Zhang

Zhou

(2010) Expression of tumor-specific antigen MAGE, GAGE and BAGE in ovarian cancer tissues and cell lines. BMC Cancer 10: 163.

274.

Zhou

Guo

Wang

Yang

. (2008) A dendritic cell-based tumour vaccine for lung cancer: full-length XAGE-1b protein-pulsed dendritic cells induce specific cytotoxic T lymphocytes in vitro. Clin Exp Immunol 153: 392–400.

275.

Zhu

Anderson

Schubart

Xiong

Imitola

Khoury

. (2005) The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 6: 1245–1252.

276.

Zhu

Zhang

Liang

Zhu

Wang

Miao

. (2014) Pancreatic cancer counterattack: MUC4 mediates Fas-independent apoptosis of antigen-specific cytotoxic T lymphocyte. Oncol Rep 31: 1768–1776.

Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential

Abstract

Keywords

Introduction

Established targets of anticancer immunotherapies

Immune checkpoint blockade: CTLA-4 and PD-1

EGFR receptor tyrosine kinase family

Cetuximab and panitumumab

Trastuzumab

Necitumumab

VEGFA and VEGF-R2

PAP

Investigational tumor antigens and their clinical potential

MUC1

Immune checkpoints: PD-L1; LAG-3; TIM-3; VISTA

PD-L1

LAG-3

TIM-3

VISTA

CTAs: NY-ESO-1 and MAGE-A3

NY-ESO-1

MAGE-A3

Oncofetal antigens: CEA and 5T4

CEA

5T4

5T4 vaccine (TroVax®)

5T4 superantigen–antibody fusion protein (naptumomab estafenatox)

PSA

Survivin

IDO1

Discussion

Footnotes

Funding

Conflict of interest statement

References